

Basic pharmacodynamics of antibacterials with clinical glycopeptides, and linezolid

Infectious Disease Clinics of North America

17, 479-501

DOI: [10.1016/s0891-5520\(03\)00065-5](https://doi.org/10.1016/s0891-5520(03)00065-5)

Citation Report

| # | ARTICLE | IF | CITATIONS |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|-----------|
| 1 | Pharmacodynamics of Telavancin (TD-6424), a Novel Bactericidal Agent, against Gram-Positive Bacteria. <i>Antimicrobial Agents and Chemotherapy</i> , 2004, 48, 3043-3050. | 1.4 | 139 |
| 2 | Effect of Ertapenem Protein Binding on Killing of Bacteria. <i>Antimicrobial Agents and Chemotherapy</i> , 2004, 48, 3419-3424. | 1.4 | 41 |
| 3 | Antimicrobial pharmacodynamics: critical interactions of 'bug and drug'. <i>Nature Reviews Microbiology</i> , 2004, 2, 289-300. | 13.6 | 825 |
| 4 | Overview of newer antimicrobial formulations for overcoming pneumococcal resistance. <i>The American Journal of Medicine: Supplement</i> , 2004, 117, 16-22. | 1.7 | 11 |
| 5 | Pharmacodynamics of antimicrobial drugs. <i>Infectious Disease Clinics of North America</i> , 2004, 18, 451-465. | 1.9 | 195 |
| 6 | Principles of use of antibacterial agents. <i>Infectious Disease Clinics of North America</i> , 2004, 18, 435-450. | 1.9 | 17 |
| 7 | Anti-infective pharmacodynamics – maximizing efficacy, minimizing toxicity. <i>Drug Discovery Today: Therapeutic Strategies</i> , 2004, 1, 505-512. | 0.5 | 6 |
| 8 | Antibiotics for gram-positive bacterial infections: vancomycin, quinupristin-dalfopristin, linezolid, and daptomycin. <i>Infectious Disease Clinics of North America</i> , 2004, 18, 651-668. | 1.9 | 41 |
| 9 | Glycopeptides in clinical development: pharmacological profile and clinical perspectives. <i>Current Opinion in Pharmacology</i> , 2004, 4, 471-478. | 1.7 | 96 |
| 10 | Pharmacokinetics and intrapulmonary concentrations of linezolid administered to critically ill patients with ventilator-associated pneumonia*. <i>Critical Care Medicine</i> , 2005, 33, 1529-1533. | 0.4 | 164 |
| 11 | Squeezing the antibiotic balloon: the impact of antimicrobial classes on emerging resistance. <i>Clinical Microbiology and Infection</i> , 2005, 11, 4-16. | 2.8 | 97 |
| 12 | New recommendations for vancomycin dosage for patients with MRSA pneumonia with various degrees of renal function impairment. <i>Journal of Infection and Chemotherapy</i> , 2005, 11, 182-188. | 0.8 | 2 |
| 13 | Four case studies to highlight some opportunities and challenges in developing anti-bacterial and anti-fungal agents. <i>Pharmaceutical Statistics</i> , 2005, 4, 253-265. | 0.7 | 2 |
| 14 | Pharmacokinetics of imipenem in healthy volunteers following administration by 2 h or 0.5 h infusion. <i>Journal of Antimicrobial Chemotherapy</i> , 2005, 56, 1163-1165. | 1.3 | 28 |
| 15 | Efficacy of Telavancin (TD-6424), a Rapidly Bactericidal Lipoglycopeptide with Multiple Mechanisms of Action, in a Murine Model of Pneumonia Induced by Methicillin-Resistant <i>Staphylococcus aureus</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2005, 49, 4344-4346. | 1.4 | 83 |
| 16 | Evaluation by Monte Carlo Simulation of the Pharmacokinetics of Two Doses of Meropenem Administered Intermittently or as a Continuous Infusion in Healthy Volunteers. <i>Antimicrobial Agents and Chemotherapy</i> , 2005, 49, 1881-1889. | 1.4 | 87 |
| 18 | Activity of three β -lactams (ertapenem, meropenem and ampicillin) against intraphagocytic <i>Listeria monocytogenes</i> and <i>Staphylococcus aureus</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2005, 55, 897-904. | 1.3 | 50 |
| 19 | Comparison of the Pharmacodynamics of Meropenem in Patients with Ventilator-Associated Pneumonia following Administration by 3-Hour Infusion or Bolus Injection. <i>Antimicrobial Agents and Chemotherapy</i> , 2005, 49, 1337-1339. | 1.4 | 138 |

| # | ARTICLE | IF | CITATIONS |
|----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 20 | Application of Pharmacokinetics and Pharmacodynamics to Antimicrobial Therapy of Community-Acquired Respiratory Tract Infections. <i>Respiration</i> , 2005, 72, 561-571. | 1.2 | 11 |
| 21 | Penetration of Piperacillin and Tazobactam into Inflamed Soft Tissue of Patients with Diabetic Foot Infection. <i>Antimicrobial Agents and Chemotherapy</i> , 2005, 49, 4368-4371. | 1.4 | 23 |
| 22 | Use of Pharmacokinetic-Pharmacodynamic Target Attainment Analyses To Support Phase 2 and 3 Dosing Strategies for Doripenem. <i>Antimicrobial Agents and Chemotherapy</i> , 2005, 49, 3944-3947. | 1.4 | 123 |
| 23 | Guidelines for the Selection of Antibacterial Therapy in Children. <i>Pediatric Clinics of North America</i> , 2005, 52, 869-894. | 0.9 | 12 |
| 24 | Pharmacokinetic studies of linezolid and teicoplanin in the critically ill. <i>Journal of Antimicrobial Chemotherapy</i> , 2005, 55, 333-340. | 1.3 | 74 |
| 25 | A retrospective analysis using Monte Carlo simulation to evaluate recommended ceftazidime dosing regimens in healthy volunteers, patients with cystic fibrosis, and patients in the intensive care unit. <i>Clinical Therapeutics</i> , 2005, 27, 762-772. | 1.1 | 55 |
| 26 | Use of Monte Carlo simulation to assess the pharmacodynamics of β -lactams against pseudomonas aeruginosa infections in children: A report from the OPTAMA program. <i>Clinical Therapeutics</i> , 2005, 27, 1820-1830. | 1.1 | 30 |
| 27 | Postantibiotic effect of antimicrobial combinations on multidrug-resistant <i>Pseudomonas aeruginosa</i> . <i>Diagnostic Microbiology and Infectious Disease</i> , 2005, 51, 113-117. | 0.8 | 23 |
| 28 | Guidelines for the Management of Adults with Hospital-acquired, Ventilator-associated, and Healthcare-associated Pneumonia. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2005, 171, 388-416. | 2.5 | 6,817 |
| 29 | Antimicrobial Therapy in Critically Ill Patients. <i>Clinical Pharmacokinetics</i> , 2005, 44, 1009-1034. | 1.6 | 316 |
| 30 | New dosing strategies for antibacterial agents in the neonate. <i>Seminars in Fetal and Neonatal Medicine</i> , 2005, 10, 185-194. | 1.1 | 88 |
| 31 | Clinical Implications of Pharmacokinetics and Pharmacodynamics of Fluoroquinolones. <i>Clinical Infectious Diseases</i> , 2005, 41, S127-S135. | 2.9 | 69 |
| 32 | Solutions to the Problem of Bacterial Resistance. <i>Treatments in Respiratory Medicine</i> , 2005, 4, 25-30. | 1.4 | 3 |
| 33 | In Vitro Susceptibility Testing Versus In Vivo Effectiveness. <i>Medical Clinics of North America</i> , 2006, 90, 1077-1088. | 1.1 | 18 |
| 34 | Pharmacokinetics and pharmacodynamics of antibiotics revisited in lungs. <i>Antibiotiques</i> , 2006, 8, 232-241. | 0.1 | 1 |
| 35 | Optimizing Antimicrobial Therapy for Gram-Positive Bloodstream Infections in Patients on Hemodialysis. <i>Advances in Chronic Kidney Disease</i> , 2006, 13, 259-270. | 0.6 | 11 |
| 37 | Dosage des Antibiotiques en Réanimation: quand et comment demander et interpréter les tests?. <i>Reanimation: Journal De La Societe De Reanimation De Langue Francaise</i> , 2006, 15, 187-192. | 0.1 | 16 |
| 38 | Antibacterial Dosing in Intensive Care. <i>Clinical Pharmacokinetics</i> , 2006, 45, 755-773. | 1.6 | 247 |

| # | ARTICLE | IF | CITATIONS |
|----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 39 | Gram-Positive Cocci Infections in Intensive Care. <i>Drugs</i> , 2006, 66, 751-768. | 4.9 | 9 |
| 40 | The effect of food on plasma and tissue concentrations of linezolid after multiple doses. <i>International Journal of Antimicrobial Agents</i> , 2006, 27, 108-112. | 1.1 | 21 |
| 41 | Community-acquired methicillin-resistant <i>Staphylococcus aureus</i> infections. <i>International Journal of Antimicrobial Agents</i> , 2006, 27, 87-96. | 1.1 | 152 |
| 42 | Pharmacodynamics: Relation to antimicrobial resistance. <i>American Journal of Infection Control</i> , 2006, 34, S38-S45. | 1.1 | 53 |
| 43 | Pharmacodynamics: Relation to Antimicrobial Resistance. <i>American Journal of Medicine</i> , 2006, 119, S37-S44. | 0.6 | 76 |
| 44 | Hospital-acquired pneumonia in the 21st century: a review of existing treatment options and their impact on patient care. <i>Expert Opinion on Pharmacotherapy</i> , 2006, 7, 1555-1569. | 0.9 | 26 |
| 46 | Teicoplanin Population Pharmacokinetic Analysis in Hospitalized Patients. <i>Therapeutic Drug Monitoring</i> , 2006, 28, 737-743. | 1.0 | 32 |
| 48 | Clinical implications and treatment of multiresistant <i>Streptococcus pneumoniae</i> pneumonia. <i>Clinical Microbiology and Infection</i> , 2006, 12, 31-41. | 2.8 | 61 |
| 49 | Diagnosis and treatment of catheter-related infections in paediatric oncology: an update. <i>Clinical Microbiology and Infection</i> , 2006, 12, 606-620. | 2.8 | 77 |
| 50 | Pharmacokinetics of cefovecin in cats. <i>Journal of Veterinary Pharmacology and Therapeutics</i> , 2006, 29, 513-524. | 0.6 | 42 |
| 51 | Recommended initial loading dose of teicoplanin, established by therapeutic drug monitoring, and outcome in terms of optimal trough level. <i>Journal of Infection and Chemotherapy</i> , 2006, 12, 185-189. | 0.8 | 34 |
| 52 | The role of pharmacodynamic research in the assessment and development of new antibacterial drugs. <i>Biochemical Pharmacology</i> , 2006, 71, 1057-1065. | 2.0 | 19 |
| 53 | Optimizing Antibiotic Treatment for Ventilator-Associated Pneumonia. <i>Pharmacotherapy</i> , 2006, 26, 204-213. | 1.2 | 27 |
| 54 | Potential Impact of Vancomycin Pulmonary Distribution on Treatment Outcomes in Patients with Methicillin-Resistant <i>Staphylococcus aureus</i> Pneumonia. <i>Pharmacotherapy</i> , 2006, 26, 539-550. | 1.2 | 68 |
| 55 | Does haemodialysis significantly affect serum linezolid concentrations in critically ill patients with renal failure? A pilot investigation. <i>Nephrology Dialysis Transplantation</i> , 2006, 21, 1402-1406. | 0.4 | 31 |
| 56 | Applying antimicrobial pharmacodynamics to resistant gram-negative pathogens. <i>American Journal of Health-System Pharmacy</i> , 2006, 63, 1346-1360. | 0.5 | 17 |
| 57 | Rational Use of Antimicrobials in Infants in Primary Care of Bahrain. <i>Journal of Tropical Pediatrics</i> , 2006, 52, 390-393. | 0.7 | 3 |
| 58 | Effect of Treatment Duration on Pharmacokinetic/Pharmacodynamic Indices Correlating with Therapeutic Efficacy of Ceftazidime in Experimental <i>Klebsiella pneumoniae</i> Lung Infection. <i>Antimicrobial Agents and Chemotherapy</i> , 2006, 50, 2919-2925. | 1.4 | 25 |

| # | ARTICLE | IF | CITATIONS |
|----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 59 | The Role of Vancomycin in the Treatment Paradigm. <i>Clinical Infectious Diseases</i> , 2006, 42, S51-S57. | 2.9 | 149 |
| 60 | Serum and Cerebrospinal Fluid Concentrations of Linezolid in Neurosurgical Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2006, 50, 3971-3976. | 1.4 | 98 |
| 61 | Pharmacodynamics of a New Cephalosporin, PPI-0903 (TAK-599), Active against Methicillin-Resistant <i>Staphylococcus aureus</i> in Murine Thigh and Lung Infection Models: Identification of an In Vivo Pharmacokinetic-Pharmacodynamic Target. <i>Antimicrobial Agents and Chemotherapy</i> , 2006, 50, 1376-1383. | 1.4 | 135 |
| 62 | The Antimicrobial Therapy Puzzle: Could Pharmacokinetic-Pharmacodynamic Relationships Be Helpful in Addressing the Issue of Appropriate Pneumonia Treatment in Critically Ill Patients?. <i>Clinical Infectious Diseases</i> , 2006, 42, 1764-1771. | 2.9 | 133 |
| 63 | Efficacy of telavancin in a murine model of bacteraemia induced by methicillin-resistant <i>Staphylococcus aureus</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2006, 58, 462-465. | 1.3 | 73 |
| 64 | Clinical Correlation of the CLSI Susceptibility Breakpoint for Piperacillin-Tazobactam against Extended-Spectrum-β-Lactamase-Producing <i>Escherichia coli</i> and <i>Klebsiella</i> Species. <i>Antimicrobial Agents and Chemotherapy</i> , 2006, 50, 2244-2247. | 1.4 | 72 |
| 65 | Population Pharmacokinetic Analysis of Panipenem/Betamipron in Patients with Various Degrees of Renal Function. <i>Chemotherapy</i> , 2006, 52, 245-253. | 0.8 | 5 |
| 66 | Pharmacodynamic Evaluation of the Intracellular Activities of Antibiotics against <i>Staphylococcus aureus</i> in a Model of THP-1 Macrophages. <i>Antimicrobial Agents and Chemotherapy</i> , 2006, 50, 841-851. | 1.4 | 228 |
| 67 | Antimicrobial Pharmacodynamics in Theory and Clinical Practice. , 0, , . | | 33 |
| 68 | Antimicrobial Resistance in <i>Haemophilus influenzae</i> . <i>Clinical Microbiology Reviews</i> , 2007, 20, 368-389. | 5.7 | 368 |
| 69 | Comparative Study of the Effects of Pyridoxine, Rifampin, and Renal Function on Hematological Adverse Events Induced by Linezolid. <i>Antimicrobial Agents and Chemotherapy</i> , 2007, 51, 2559-2563. | 1.4 | 58 |
| 70 | Pharmacokinetics of Aztreonam in Healthy Subjects and Patients with Cystic Fibrosis and Evaluation of Dose-Exposure Relationships Using Monte Carlo Simulation. <i>Antimicrobial Agents and Chemotherapy</i> , 2007, 51, 3049-3055. | 1.4 | 50 |
| 71 | In Vivo Pharmacodynamic Activity of the Glycopeptide Dalbavancin. <i>Antimicrobial Agents and Chemotherapy</i> , 2007, 51, 1633-1642. | 1.4 | 102 |
| 72 | Single-Dose Oral Amoxicillin or Linezolid for Prophylaxis of Experimental Endocarditis Due to Vancomycin-Susceptible and Vancomycin-Resistant <i>Enterococcus faecalis</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2007, 51, 1661-1665. | 1.4 | 6 |
| 73 | Pharmacokinetics of Penicillin G in Infants with a Gestational Age of Less than 32 Weeks. <i>Antimicrobial Agents and Chemotherapy</i> , 2007, 51, 3720-3725. | 1.4 | 23 |
| 74 | Vancomycin Disposition and Penetration into Ventricular Fluid of the Central Nervous System following Intravenous Therapy in Patients with Cerebrospinal Devices. <i>Pediatric Neurosurgery</i> , 2007, 43, 449-455. | 0.4 | 24 |
| 75 | Once-Weekly Micafungin Therapy Is as Effective as Daily Therapy for Disseminated Candidiasis in Mice with Persistent Neutropenia. <i>Antimicrobial Agents and Chemotherapy</i> , 2007, 51, 968-974. | 1.4 | 102 |
| 76 | Concentration-Effect Relationship of Ceftazidime Explains Why the Time above the MIC Is 40 Percent for a Static Effect In Vivo. <i>Antimicrobial Agents and Chemotherapy</i> , 2007, 51, 3449-3451. | 1.4 | 67 |

| # | ARTICLE | IF | CITATIONS |
|----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 77 | Documento de Consenso sobre pneumonia nosocomial11 Sociedade Portuguesa de Pneumologia e Sociedade Portuguesa de Cuidados Intensivos / Portuguese Society of Pulmonology and Intensive Care Society,22O presente documento Á© simultaneamente publicado na Revista Portuguesa de Medicina Intensiva (2007; 14(1):7-30) / This work is published simultaneously in the Portuguese Journal of Intensive Care Medicine (2007; 14(1):7-30). The Society of Thoracic Surgeons Practice Guideline Series: Antibiotic Prophylaxis in Cardiac Surgery. Part II: Antibiotic Choice. For the full text of the STS Guideline on Antibiotic Prophylaxis in Cardiac Surgery, as well as other titles in the STS Practice Guideline Series, visit http://www.sts.org/sections/aboutthesociety/practiceguidelines/ at the official STS website (www.sts.org). Annals of Thoracic Surgery, 2007, 83, 1569-1576. | 0.7 | 17 |
| 78 | Oral β -lactams applied to uncomplicated infections of skin and skin structures. Diagnostic Microbiology and Infectious Disease, 2007, 57, S55-S65. | 0.7 | 369 |
| 79 | Oral β -lactams applied to uncomplicated infections of skin and skin structures. Diagnostic Microbiology and Infectious Disease, 2007, 57, S55-S65. | 0.8 | 24 |
| 80 | Review of the spectrum and potency of orally administered cephalosporins and amoxicillin/clavulanate. Diagnostic Microbiology and Infectious Disease, 2007, 57, S5-S12. | 0.8 | 37 |
| 81 | Consensus document on nosocomial pneumonia. Revista Portuguesa De Pneumologia, 2007, 13, 419-486. | 0.7 | 10 |
| 82 | Pharmacokinetic and Pharmacodynamic Aspects of Antibiotic Use in High-Risk Populations. Infectious Disease Clinics of North America, 2007, 21, 821-846. | 1.9 | 27 |
| 83 | Linezolid: effectiveness and safety for approved and off-label indications. Expert Opinion on Pharmacotherapy, 2007, 8, 2381-2400. | 0.9 | 32 |
| 85 | Peritoneal penetration and pharmacodynamic exposure of intravenous cefozopran in abdominal surgery patients. International Journal of Antimicrobial Agents, 2007, 30, 352-355. | 1.1 | 15 |
| 86 | Combating resistance: application of the emerging science of pharmacokinetics and pharmacodynamics. International Journal of Antimicrobial Agents, 2007, 30, 122-126. | 1.1 | 9 |
| 87 | Hospital-Acquired Pneumonia Caused by Staphylococcus aureus. , 0, , 107-129. | | 0 |
| 89 | Continuous vs. intermittent cefotaxime administration in patients with chronic obstructive pulmonary disease and respiratory tract infections: pharmacokinetics/pharmacodynamics, bacterial susceptibility and clinical efficacy. British Journal of Clinical Pharmacology, 2007, 63, 100-109. | 1.1 | 49 |
| 90 | Preparation of aromatic β -Selenolactams and their bioactivities as agricultural chemicals. Archives of Pharmacal Research, 2007, 30, 938-944. | 2.7 | 6 |
| 91 | Peritoneal pharmacokinetics of cefepime in laparotomy patients with inflammatory bowel disease, and dosage considerations for surgical intra-abdominal infections based on pharmacodynamic assessment. Journal of Infection and Chemotherapy, 2008, 14, 110-116. | 0.8 | 5 |
| 92 | Ciprofloxacin pharmacokinetics in critically ill patients: A prospective cohort study. Journal of Critical Care, 2008, 23, 422-430. | 1.0 | 94 |
| 93 | Recommendations to achieve rapid therapeutic teicoplanin plasma concentrations in adult hospitalised patients treated for sepsis. International Journal of Antimicrobial Agents, 2008, 32, 455-458. | 1.1 | 605 |
| 94 | Pharmacokinetics/pharmacodynamics of antibacterials in the Intensive Care Unit: setting appropriate dosing regimens. International Journal of Antimicrobial Agents, 2008, 32, 294-301.e7. | 1.1 | 87 |
| 95 | Continuous versus intermittent infusion of temocillin, a directed spectrum penicillin for intensive care patients with nosocomial pneumonia: stability, compatibility, population pharmacokinetic studies and breakpoint selection. Journal of Antimicrobial Chemotherapy, 2008, 61, 382-388. | 1.3 | 78 |
| 96 | Pharmacokinetics and Pharmacodynamic Assessment of Imipenem in the Intraperitoneal Fluid of Abdominal Surgery Patients. Chemotherapy, 2008, 54, 131-139. | 0.8 | 16 |

| # | ARTICLE | IF | CITATIONS |
|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 97 | Linezolid for the treatment of skin and soft-tissue infections. <i>Expert Review of Dermatology</i> , 2008, 3, 539-548. | 0.3 | 1 |
| 98 | In Vivo Pharmacodynamics of Ceftobiprole against Multiple Bacterial Pathogens in Murine Thigh and Lung Infection Models. <i>Antimicrobial Agents and Chemotherapy</i> , 2008, 52, 3492-3496. | 1.4 | 76 |
| 99 | Efficacies of Ceftobiprole Medocaril and Comparators in a Rabbit Model of Osteomyelitis Due to Methicillin-Resistant <i>Staphylococcus aureus</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2008, 52, 1618-1622. | 1.4 | 29 |
| 100 | Temocillin revived. <i>Journal of Antimicrobial Chemotherapy</i> , 2008, 63, 243-245. | 1.3 | 107 |
| 101 | The role of carbapenems in the treatment of severe nosocomial respiratory tract infections. <i>Expert Opinion on Pharmacotherapy</i> , 2008, 9, 561-575. | 0.9 | 46 |
| 102 | Does sugar cause clotting? Intensive insulin treatment and activation of coagulation*. <i>Critical Care Medicine</i> , 2008, 36, 1657-1658. | 0.4 | 2 |
| 103 | Trust one who has gone through it*. <i>Critical Care Medicine</i> , 2008, 36, 1643-1644. | 0.4 | 5 |
| 104 | Antibiotic resistance—What’s dosing got to do with it?. <i>Critical Care Medicine</i> , 2008, 36, 2433-2440. | 0.4 | 299 |
| 105 | Atrial fibrillation in the critically ill: Common sense for a common problem*. <i>Critical Care Medicine</i> , 2008, 36, 1681-1682. | 0.4 | 5 |
| 106 | Lost in (knowledge) translation: “All breakthrough, no follow through”*. <i>Critical Care Medicine</i> , 2008, 36, 1654-1655. | 0.4 | 10 |
| 107 | Continuous infusion of β -lactams in the intensive care unit—Best way to hit the target?*. <i>Critical Care Medicine</i> , 2008, 36, 1663-1664. | 0.4 | 15 |
| 108 | E-CPR — Is there E-nough E-vidence to reach a “tipping point” for rapid deployment?*. <i>Critical Care Medicine</i> , 2008, 36, 1679-1681. | 0.4 | 4 |
| 109 | What is the score with mortality predictions in acute lung injury?*. <i>Critical Care Medicine</i> , 2008, 36, 1644-1646. | 0.4 | 1 |
| 110 | Ertapenem clearance during modeled continuous renal replacement therapy. <i>International Journal of Artificial Organs</i> , 2008, 31, 1027-1034. | 0.7 | 30 |
| 111 | Can B-type natriuretic peptide liberate us from the task of mechanical ventilation weaning?*. <i>Critical Care Medicine</i> , 2008, 36, 1646-1647. | 0.4 | 1 |
| 112 | The interleukin-6 gene and critical illness: Is inflammatory gene variation the key to personalized medicine in the intensive care unit?*. <i>Critical Care Medicine</i> , 2008, 36, 1647-1649. | 0.4 | 2 |
| 113 | The insulin, glucose, ischemia, and inflammation conundrum*. <i>Critical Care Medicine</i> , 2008, 36, 1673-1674. | 0.4 | 1 |
| 114 | From acute renal failure to acute kidney injury: Emerging concepts*. <i>Critical Care Medicine</i> , 2008, 36, 1641-1642. | 0.4 | 14 |

| # | ARTICLE | IF | CITATIONS |
|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 115 | Strategies to reduce neuronal cell death in bacterial meningitis*. Critical Care Medicine, 2008, 36, 1678-1679. | 0.4 | 1 |
| 116 | Hydroxyethyl starch: Under the microscope*. Critical Care Medicine, 2008, 36, 1670-1671. | 0.4 | 0 |
| 117 | Pyrexia of uncertain overtones*. Critical Care Medicine, 2008, 36, 1669-1670. | 0.4 | 0 |
| 118 | Flow or no flow: That is the question!*. Critical Care Medicine, 2008, 36, 1677-1678. | 0.4 | 0 |
| 119 | Novel molecular strategy to prevent pulmonary edema*. Critical Care Medicine, 2008, 36, 1671-1673. | 0.4 | 1 |
| 120 | Teasing and skinning muscles in sepsis research*. Critical Care Medicine, 2008, 36, 1674-1675. | 0.4 | 0 |
| 121 | Continuous renal replacement therapy-induced alkalosis in intensive care unit patients: The questions start here*. Critical Care Medicine, 2008, 36, 1665-1666. | 0.4 | 2 |
| 122 | Moving toward preventive therapy in acute lung injury*. Critical Care Medicine, 2008, 36, 1666-1667. | 0.4 | 0 |
| 123 | Corticosteroids and septic shock: A new episode of a never-ceasing story?*. Critical Care Medicine, 2008, 36, 1658-1659. | 0.4 | 0 |
| 124 | The transfusion of pre storage leukoreduced packed red blood cells to injured patients*. Critical Care Medicine, 2008, 36, 1661-1662. | 0.4 | 4 |
| 125 | What do families know? A question of interpretation*. Critical Care Medicine, 2008, 36, 1683-1684. | 0.4 | 0 |
| 126 | Between critical illness and hospital discharge: Prolonged acute mechanical ventilation*. Critical Care Medicine, 2008, 36, 1651-1652. | 0.4 | 2 |
| 127 | Hypothermia hype: Is it worth it?*. Critical Care Medicine, 2008, 36, 1676-1677. | 0.4 | 3 |
| 128 | Should sedation be standardized in the intensive care unit?*. Critical Care Medicine, 2008, 36, 1649-1651. | 0.4 | 15 |
| 129 | Delayed gastric emptying in critical illness: Is enhanced enterogastric inhibition with cholecystokinin and peptide YY involved?*. Critical Care Medicine, 2008, 36, 1655-1656. | 0.4 | 2 |
| 130 | Genes and sepsis: How tight is the fit?*. Critical Care Medicine, 2008, 36, 1652-1654. | 0.4 | 3 |
| 131 | Life after intensive care—It's life—but not as we know it!*. Critical Care Medicine, 2008, 36, 1668-1669. | 0.4 | 6 |
| 132 | Calcitonin peptides—The mediators in sepsis or just another fairy tale?*. Critical Care Medicine, 2008, 36, 1684-1687. | 0.4 | 16 |

| # | ARTICLE | IF | CITATIONS |
|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 133 | Continuous Infusion of Time-dependent Antibiotics. <i>Clinical Pulmonary Medicine</i> , 2008, 15, 167-172. | 0.3 | 1 |
| 134 | Meropenem Pharmacokinetics, Pharmacodynamics, and Monte Carlo Simulation in the Neonate. <i>Pediatric Infectious Disease Journal</i> , 2008, 27, 794-799. | 1.1 | 79 |
| 135 | Enhanced and earlier detection of bacteremia and fungemia by multiplex polymerase chain reaction: How much enhanced, how much earlier, and at what cost?*. <i>Critical Care Medicine</i> , 2008, 36, 1660-1661. | 0.4 | 11 |
| 136 | Continuous regional arterial infusion therapy with biapenem and nafamostat mesilate for severe acute pancreatitis. <i>Suizo</i> , 2008, 23, 578-586. | 0.1 | 2 |
| 137 | Pharmacokinetics and Pharmacodynamics of Antibiotics : General Concepts and Recent Advances. <i>Infection and Chemotherapy</i> , 2008, 40, 140. | 1.0 | 2 |
| 138 | Vancomycin Continuous Infusion as Prophylaxis for Vascular Surgery. <i>Therapeutic Drug Monitoring</i> , 2009, 31, 786-788. | 1.0 | 5 |
| 139 | Rationale for Revised Penicillin Susceptibility Breakpoints versus <i>Streptococcus pneumoniae</i> : Coping with Antimicrobial Susceptibility in an Era of Resistance. <i>Clinical Infectious Diseases</i> , 2009, 48, 1596-1600. | 2.9 | 163 |
| 140 | Resurgence of <i>Pseudomonas</i> Endocarditis in Detroit, 2006-2008. <i>Medicine (United States)</i> , 2009, 88, 294-301. | 0.4 | 53 |
| 141 | New Semiphysiological Absorption Model To Assess the Pharmacodynamic Profile of Cefuroxime Axetil Using Nonparametric and Parametric Population Pharmacokinetics. <i>Antimicrobial Agents and Chemotherapy</i> , 2009, 53, 3462-3471. | 1.4 | 19 |
| 142 | Mechanism and implication of cephalosporin penetration into oropharyngeal mucosa. <i>Journal of Infection and Chemotherapy</i> , 2009, 15, 70-74. | 0.8 | 8 |
| 143 | Effect of various estimates of renal function on prediction of vancomycin concentration by the population mean and Bayesian methods. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2009, 34, 465-472. | 0.7 | 11 |
| 144 | Antibiotics for Gram-Positive Bacterial Infections: Vancomycin, Teicoplanin, Quinupristin/Dalfopristin, Oxazolidinones, Daptomycin, Dalbavancin, and Telavancin. <i>Infectious Disease Clinics of North America</i> , 2009, 23, 965-982. | 1.9 | 43 |
| 145 | Comparison of the pharmacokinetics and pharmacodynamic profile of carumonam in cystic fibrosis patients and healthy volunteers. <i>Diagnostic Microbiology and Infectious Disease</i> , 2009, 65, 130-141. | 0.8 | 17 |
| 147 | Correlation between free and total vancomycin serum concentrations in patients treated for Gram-positive infections. <i>International Journal of Antimicrobial Agents</i> , 2009, 34, 555-560. | 1.1 | 55 |
| 148 | Epidemiology, Prevention and Management of Ventriculoperitoneal Shunt Infections in Children. <i>Pediatric Neurosurgery</i> , 2009, 45, 325-336. | 0.4 | 113 |
| 149 | Therapeutic monitoring of vancomycin in adult patients: A consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. <i>American Journal of Health-System Pharmacy</i> , 2009, 66, 82-98. | 0.5 | 1,502 |
| 150 | Promising Antituberculosis Activity of the Oxazolidinone PNU-100480 Relative to That of Linezolid in a Murine Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2009, 53, 1314-1319. | 1.4 | 185 |
| 151 | Antistaphylococcal Agents. <i>Infectious Disease Clinics of North America</i> , 2009, 23, 99-131. | 1.9 | 9 |

| # | ARTICLE | IF | CITATIONS |
|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 152 | Pharmacokinetics and Pharmacodynamics of Antibacterial Agents. Infectious Disease Clinics of North America, 2009, 23, 791-815. | 1.9 | 387 |
| 153 | Pharmacokinetic issues for antibiotics in the critically ill patient. Critical Care Medicine, 2009, 37, 840-851. | 0.4 | 755 |
| 154 | The jury is still out on continuous infusion of β -lactam antibiotics in intensive care patients*. Critical Care Medicine, 2009, 37, 2137-2138. | 0.4 | 8 |
| 155 | Optimizing Antibiotic Use in the Intensive Care Unit. Clinical Pulmonary Medicine, 2010, 17, 162-169. | 0.3 | 1 |
| 156 | Pharmacokinetics, Pharmacodynamics, and Monte Carlo Simulation. Pediatric Infectious Disease Journal, 2010, 29, 1043-1046. | 1.1 | 42 |
| 157 | Vancomycin, unbeatable for methicillin-resistant Staphylococcus aureus hospital-acquired pneumonia? Really?*. Critical Care Medicine, 2010, 38, 1910-1912. | 0.4 | 4 |
| 158 | Nosocomial methicillin-resistant staphylococcus aureus (MRSA) pneumonia: linezolid or vancomycin? - comparison of pharmacology and clinical efficacy. European Journal of Medical Research, 2010, 15, 507. | 0.9 | 44 |
| 159 | Significance of Protein Binding in Pharmacokinetics and Pharmacodynamics. Journal of Pharmaceutical Sciences, 2010, 99, 1107-1122. | 1.6 | 267 |
| 160 | Pharmacokinetic/Pharmacodynamic Investigation of Colistin against <i>Pseudomonas aeruginosa</i> Using an <i>In Vitro</i> Model. Antimicrobial Agents and Chemotherapy, 2010, 54, 3783-3789. | 1.4 | 150 |
| 161 | Pharmacokinetic-Pharmacodynamic Assessment of Faropenem in a Lethal Murine <i>Bacillus anthracis</i> Inhalation Postexposure Prophylaxis Model. Antimicrobial Agents and Chemotherapy, 2010, 54, 1678-1683. | 1.4 | 11 |
| 162 | Generic Vancomycin Products Fail <i>In Vivo</i> despite Being Pharmaceutical Equivalents of the Innovator. Antimicrobial Agents and Chemotherapy, 2010, 54, 3271-3279. | 1.4 | 88 |
| 163 | <i>In Vivo</i> Efficacy of Simulated Human Dosing Regimens of Prolonged-Infusion Doripenem against Carbapenemase-Producing <i>Klebsiella pneumoniae</i> . Antimicrobial Agents and Chemotherapy, 2010, 54, 4112-4115. | 1.4 | 50 |
| 164 | Cephalosporin MIC creep among gonococci: time for a pharmacodynamic rethink?. Journal of Antimicrobial Chemotherapy, 2010, 65, 2141-2148. | 1.3 | 154 |
| 165 | <i>In Vivo</i> Pharmacodynamics of New Lipopeptide MX-2401. Antimicrobial Agents and Chemotherapy, 2010, 54, 5092-5098. | 1.4 | 21 |
| 166 | Optimal Antibiotic Therapy in the Management of the Lung of the Critically Ill. Current Respiratory Medicine Reviews, 2010, 6, 253-263. | 0.1 | 0 |
| 167 | Intra- and Extracellular Activities of Dicloxacillin against <i>Staphylococcus aureus</i> <i>In Vivo</i> and <i>In Vitro</i> . Antimicrobial Agents and Chemotherapy, 2010, 54, 2391-2400. | 1.4 | 21 |
| 169 | <i>In vivo</i> development of antimicrobial resistance in <i>Pseudomonas aeruginosa</i> strains isolated from the lower respiratory tract of Intensive Care Unit patients with nosocomial pneumonia and receiving antipseudomonal therapy. International Journal of Antimicrobial Agents, 2010, 36, 513-522. | 1.1 | 72 |
| 170 | Pharmacokinetic/pharmacodynamic (PK/PD) considerations in the management of Gram-positive bacteraemia. International Journal of Antimicrobial Agents, 2010, 36, S33-S39. | 1.1 | 14 |

| # | ARTICLE | IF | CITATIONS |
|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 171 | Augmented Renal Clearance. <i>Clinical Pharmacokinetics</i> , 2010, 49, 1-16. | 1.6 | 313 |
| 172 | The importance of tissue penetration in achieving successful antimicrobial treatment of nosocomial pneumonia and complicated skin and soft-tissue infections caused by methicillin-resistant <i>Staphylococcus aureus</i> : vancomycin and linezolid. <i>Current Medical Research and Opinion</i> , 2010, 26, 571-588. | 0.9 | 110 |
| 173 | Use of vancomycin pharmacokinetic-pharmacodynamic properties in the treatment of MRSA infections. <i>Expert Review of Anti-Infective Therapy</i> , 2010, 8, 95-106. | 2.0 | 67 |
| 174 | Optimal airway antimicrobial therapy for cystic fibrosis: the role of inhaled aztreonam lysine. <i>Expert Opinion on Pharmacotherapy</i> , 2010, 11, 1373-1385. | 0.9 | 17 |
| 175 | Antibiotics in critically ill patients: a systematic review of the pharmacokinetics of β -lactams. <i>Critical Care</i> , 2011, 15, R206. | 2.5 | 316 |
| 176 | Pharmacodynamics of meropenem in critically ill patients with febrile neutropenia and bacteraemia. <i>International Journal of Antimicrobial Agents</i> , 2011, 38, 231-236. | 1.1 | 37 |
| 177 | Antibiotic policy. <i>International Journal of Antimicrobial Agents</i> , 2011, 38, 11-20. | 1.1 | 56 |
| 178 | Antimicrobial Pharmacokinetic and Pharmacodynamic Issues in the Critically Ill with Severe Sepsis and Septic Shock. <i>Critical Care Clinics</i> , 2011, 27, 19-34. | 1.0 | 118 |
| 179 | Can Pharmacokinetic and Pharmacodynamic Principles Be Applied to the Treatment of Multidrug-Resistant <i>Acinetobacter</i> ?. <i>Annals of Pharmacotherapy</i> , 2011, 45, 229-240. | 0.9 | 13 |
| 180 | Antibiotics for Gram-Positive Bacterial Infection: Vancomycin, Teicoplanin, Quinupristin/Dalfopristin, Oxazolidinones, Daptomycin, Telavancin, and Ceftaroline. <i>Medical Clinics of North America</i> , 2011, 95, 723-742. | 1.1 | 11 |
| 181 | The Medicinal Chemistry of Tuberculosis Chemotherapy. <i>Topics in Medicinal Chemistry</i> , 2011, , 47-124. | 0.4 | 17 |
| 182 | Ceftaroline Fosamil: A Novel Broad-Spectrum Cephalosporin with Activity Against Methicillin-Resistant <i>Staphylococcus aureus</i> . <i>Annals of Pharmacotherapy</i> , 2011, 45, 1384-1398. | 0.9 | 28 |
| 183 | Controlling Drug Release in Oral Product Development Programs: An Industrial Perspective. , 2011, , 49-69. | | 3 |
| 184 | Sepsis: new strategies for management. <i>Critical Care</i> , 2011, 15, 306. | 2.5 | 0 |
| 185 | Cefuroxime Pharmacokinetics in Pediatric Cardiovascular Surgery Patients Undergoing Cardiopulmonary Bypass. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2011, 25, 425-430. | 0.6 | 22 |
| 186 | Successful Utilization of High-Flux Hemodialysis for Treatment of Vancomycin Toxicity in a Child. <i>Case Reports in Pediatrics</i> , 2011, 2011, 1-4. | 0.2 | 11 |
| 187 | Teicoplanin Dosing Strategy for Treatment of <i>Staphylococcus aureus</i> in Korean Patients with Neutropenic Fever. <i>Yonsei Medical Journal</i> , 2011, 52, 616. | 0.9 | 16 |
| 188 | Clinical Pharmacology of Anti-Infective Drugs. , 2011, , 1160-1211. | | 7 |

| # | ARTICLE | IF | CITATIONS |
|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 189 | Triple Therapy with Ecabet Sodium, Amoxicillin and Lansoprazole for 2 Weeks as the Rescue Regimen for H. pylori Infection. <i>Internal Medicine</i> , 2011, 50, 369-374. | 0.3 | 14 |
| 190 | Novel gastroretentive controlled-release drug delivery system for amoxicillin therapy in veterinary medicine. <i>Journal of Veterinary Pharmacology and Therapeutics</i> , 2011, 34, 487-493. | 0.6 | 7 |
| 191 | Pharmacokinetics of ceftiofur crystalline-free acid sterile suspension in the equine. <i>Journal of Veterinary Pharmacology and Therapeutics</i> , 2011, 34, 476-481. | 0.6 | 35 |
| 193 | WSES consensus conference: Guidelines for first-line management of intra-abdominal infections. <i>World Journal of Emergency Surgery</i> , 2011, 6, 2. | 2.1 | 57 |
| 194 | Vancomycin dosing and monitoring 2 years after the guidelines. <i>Expert Review of Anti-Infective Therapy</i> , 2011, 9, 657-667. | 2.0 | 20 |
| 195 | Refining Vancomycin Protein Binding Estimates: Identification of Clinical Factors That Influence Protein Binding. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 4277-4282. | 1.4 | 69 |
| 196 | Vancomycin: We Can't Get There From Here. <i>Clinical Infectious Diseases</i> , 2011, 52, 969-974. | 2.9 | 214 |
| 197 | Relationship between Vancomycin Trough Concentrations and Nephrotoxicity: a Prospective Multicenter Trial. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 5475-5479. | 1.4 | 213 |
| 198 | Improving antibiotic dosing in special situations in the ICU. <i>Current Opinion in Critical Care</i> , 2012, 18, 460-471. | 1.6 | 86 |
| 199 | Is Peak Concentration Needed in Therapeutic Drug Monitoring of Vancomycin? A Pharmacokinetic-Pharmacodynamic Analysis in Patients with Methicillin-Resistant <i>Staphylococcus aureus</i> Pneumonia. <i>Chemotherapy</i> , 2012, 58, 308-312. | 0.8 | 100 |
| 200 | Pharmacodynamics of TD-1792, a Novel Glycopeptide-Cephalosporin Heterodimer Antibiotic Used against Gram-Positive Bacteria, in a Neutropenic Murine Thigh Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 1578-1583. | 1.4 | 25 |
| 201 | Evaluation of Once-Daily Vancomycin against Methicillin-Resistant <i>Staphylococcus aureus</i> in a Hollow-Fiber Infection Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 682-686. | 1.4 | 33 |
| 202 | A Simplified Oral Flucloxacillin Absorption Test for Patients Requiring Long-Term Treatment. <i>Therapeutic Drug Monitoring</i> , 2012, 34, 356-358. | 1.0 | 8 |
| 203 | Risk factors for 30-day mortality in adult patients with pneumococcal bacteraemia, and the impact of antimicrobial resistance on clinical outcomes. <i>Epidemiology and Infection</i> , 2012, 140, 1267-1276. | 1.0 | 15 |
| 204 | Applications of Pharmacokinetic and Pharmacodynamic Principles to Optimize Drug Dosage Selection. , 2012, , 175-196. | | 0 |
| 205 | Clinical and microbiological efficacy of continuous versus intermittent application of meropenem in critically ill patients: a randomized open-label controlled trial. <i>Critical Care</i> , 2012, 16, R113. | 2.5 | 119 |
| 206 | In vitro synergy, pharmacodynamics, and postantibiotic effect of 11 antimicrobial agents against <i>Rhodococcus equi</i> . <i>Veterinary Microbiology</i> , 2012, 160, 207-213. | 0.8 | 51 |
| 207 | The role of pharmacokinetics/pharmacodynamics in setting clinical MIC breakpoints: the EUCAST approach. <i>Clinical Microbiology and Infection</i> , 2012, 18, E37-E45. | 2.8 | 232 |

| # | ARTICLE | IF | CITATIONS |
|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 208 | Pharmacodynamics of doripenem in critically ill patients with ventilator-associated Gram-negative bacilli pneumonia. <i>International Journal of Antimicrobial Agents</i> , 2012, 40, 434-439. | 1.1 | 24 |
| 209 | Continuous beta-lactam infusion in critically ill patients: the clinical evidence. <i>Annals of Intensive Care</i> , 2012, 2, 37. | 2.2 | 85 |
| 210 | Continuous infusion of antibiotics in the critically ill: The new holy grail for beta-lactams and vancomycin?. <i>Annals of Intensive Care</i> , 2012, 2, 22. | 2.2 | 41 |
| 211 | Reduced vancomycin susceptibility among clinical <i>Staphylococcus aureus</i> isolates (the MIC Creep™): implications for therapy. <i>F1000 Medicine Reports</i> , 2012, 4, 4. | 2.9 | 90 |
| 212 | Importance of High Creatinine Clearance for Antibacterial Treatment in Sepsis. , 2012, , 171-197. | | 0 |
| 213 | Vancomycin AUC ₂₄ /MIC Ratio in Patients with Complicated Bacteremia and Infective Endocarditis Due to Methicillin-Resistant <i>Staphylococcus aureus</i> and Its Association with Attributable Mortality during Hospitalization. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 634-638. | 1.4 | 99 |
| 214 | Loading Dose Required to Achieve Rapid Therapeutic Teicoplanin Trough Plasma Concentration in Patients with Multidrug-Resistant <i>Gram-Positive</i> Infections. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2012, 110, 416-420. | 1.2 | 15 |
| 215 | β-lactam pharmacokinetics and pharmacodynamics in critically ill patients and strategies for dose optimization: A structured review. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2012, 39, 489-496. | 0.9 | 74 |
| 216 | A survey of beta-lactam antibiotics and vancomycin dosing strategies in intensive care units and general wards in Belgian hospitals. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2013, 32, 763-768. | 1.3 | 39 |
| 218 | Prescribing Habits of Vancomycin in the Emergency Department: Are We Dosing Appropriately?. <i>Journal of Emergency Medicine</i> , 2013, 44, 979-984. | 0.3 | 10 |
| 219 | When is Protein Binding Important?*. <i>Journal of Pharmaceutical Sciences</i> , 2013, 102, 3458-3467. | 1.6 | 64 |
| 220 | <i>In Vitro</i> and <i>In Vivo</i> Efficacy of β-Lactams against Replicating and Slowly Growing/Nonreplicating <i>Mycobacterium tuberculosis</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 2506-2510. | 1.4 | 65 |
| 221 | β-Lactam therapeutic drug monitoring in the critically ill: optimising drug exposure in patients with fluctuating renal function and hypoalbuminaemia. <i>International Journal of Antimicrobial Agents</i> , 2013, 41, 162-166. | 1.1 | 65 |
| 222 | Témocilline, une alternative aux carbapénèmes pour traiter les infections à bactéries résistantes aux C3G?. <i>Journal Des Anti-infectieux</i> , 2013, 15, 60-70. | 0.1 | 3 |
| 223 | Implementation of a protocol for administration of vancomycin by continuous infusion: pharmacokinetic, pharmacodynamic and toxicological aspects. <i>International Journal of Antimicrobial Agents</i> , 2013, 41, 439-446. | 1.1 | 40 |
| 224 | Synthetic amphiphiles as therapeutic antibacterials: lessons on bactericidal efficacy and cytotoxicity and potential application as an adjuvant in antimicrobial chemotherapy. <i>Journal of Materials Chemistry B</i> , 2013, 1, 2612. | 2.9 | 17 |
| 225 | Optimal exposures of ceftazidime predict the probability of microbiological and clinical outcome in the treatment of nosocomial pneumonia. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 900-906. | 1.3 | 105 |
| 226 | Inoculum Effects of Ceftobiprole, Daptomycin, Linezolid, and Vancomycin with <i>Staphylococcus aureus</i> and <i>Streptococcus pneumoniae</i> at Inocula of 10 ⁵ and 10 ⁷ CFU Injected into Opposite Thighs of Neutropenic Mice. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 1434-1441. | 1.4 | 48 |

| # | ARTICLE | IF | CITATIONS |
|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 227 | Pharmacodynamic Variability beyond That Explained by MICs. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 1730-1735. | 1.4 | 12 |
| 228 | Defining Antibiotic Dosing in Lung Infections. <i>Clinical Pulmonary Medicine</i> , 2013, 20, 121-128. | 0.3 | 18 |
| 229 | Risk Factors for a Low Linezolid Trough Plasma Concentration in Acute Infections. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 1913-1917. | 1.4 | 53 |
| 230 | Human Simulated Studies of Aztreonam and Aztreonam-Avibactam To Evaluate Activity against Challenging Gram-Negative Organisms, Including Metallo- β -Lactamase Producers. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 3299-3306. | 1.4 | 92 |
| 231 | Reply to "Breakthrough Bacteremia by Linezolid-Susceptible <i>Enterococcus faecalis</i> under Linezolid Treatment in a Severe Polytrauma Patient". <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 6413-6414. | 1.4 | 0 |
| 232 | Vancomycin AUC/MIC Ratio and 30-Day Mortality in Patients with <i>Staphylococcus aureus</i> Bacteremia. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 1654-1663. | 1.4 | 176 |
| 233 | <i>In Vivo</i> Activities of Ceftolozane, a New Cephalosporin, with and without Tazobactam against <i>Pseudomonas aeruginosa</i> and Enterobacteriaceae, Including Strains with Extended-Spectrum β -Lactamases, in the Thighs of Neutropenic Mice. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 1577-1582. | 1.4 | 118 |
| 234 | High Rate of Per Oral Mecillinam Treatment Failure in Community-Acquired Urinary Tract Infections Caused by ESBL-Producing <i>Escherichia coli</i> . <i>PLoS ONE</i> , 2014, 9, e85889. | 1.1 | 55 |
| 237 | Exposure to Ceftobiprole Is Associated with Microbiological Eradication and Clinical Cure in Patients with Nosocomial Pneumonia. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 2512-2519. | 1.4 | 43 |
| 238 | Activities of Ceftazidime and Avibactam against β -Lactamase-Producing Enterobacteriaceae in a Hollow-Fiber Pharmacodynamic Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 3366-3372. | 1.4 | 74 |
| 239 | The pathway-specific regulatory genes, <i>tei15*</i> and <i>tei16*</i> , are the master switches of teicoplanin production in <i>Actinoplanes teichomyceticus</i> . <i>Applied Microbiology and Biotechnology</i> , 2014, 98, 9295-9309. | 1.7 | 36 |
| 240 | Sitafloxacin-based third-line rescue regimens for <i>Helicobacter pylori</i> infection in Japan. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2014, 29, 487-493. | 1.4 | 32 |
| 241 | Effect of dosing schemes of amoxicillin on eradication rates of <i>Helicobacter pylori</i> with amoxicillin-based triple therapy. <i>Journal of Clinical Pharmacology</i> , 2014, 54, 258-266. | 1.0 | 42 |
| 242 | Low or High Doses of Cefquinome Targeting Low or High Bacterial Inocula Cure <i>Klebsiella pneumoniae</i> Lung Infections but Differentially Impact the Levels of Antibiotic Resistance in Fecal Flora. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 1744-1748. | 1.4 | 37 |
| 243 | Pharmacodynamics of Cefquinome in a Neutropenic Mouse Thigh Model of <i>Staphylococcus aureus</i> Infection. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 3008-3012. | 1.4 | 41 |
| 244 | Glycopeptides. , 2014, , 279-322. | | 0 |
| 245 | Introduction to Pharmacodynamics. , 2014, , 3-22. | | 2 |
| 247 | Population Pharmacokinetic-Pharmacodynamic (PK/PD) Modeling of Anti-infective Agents and Its Applications to Individualized Therapy. , 2014, , 113-134. | | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 248 | <i>In Vivo</i> Efficacy of Human Simulated Regimens of Carbapenems and Comparator Agents against NDM-1-Producing Enterobacteriaceae. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 1671-1677. | 1.4 | 32 |
| 249 | Impact of Renal Function on the Pharmacokinetics and Safety of Ceftolozane-Tazobactam. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 2249-2255. | 1.4 | 67 |
| 250 | Application of pharmacokinetic/pharmacodynamic modelling and simulation for the prediction of target attainment of ceftobiprole against methicillin-resistant <i>Staphylococcus aureus</i> using minimum inhibitory concentration and time-kill curve based approaches. <i>International Journal of Antimicrobial Agents</i> , 2014, 43, 60-67. | 1.1 | 19 |
| 251 | Pharmacokinetic/pharmacodynamic modelling approaches in paediatric infectious diseases and immunology. <i>Advanced Drug Delivery Reviews</i> , 2014, 73, 127-139. | 6.6 | 33 |
| 252 | Evaluation of Imipenem for Prophylaxis and Therapy of <i>Yersinia pestis</i> Delivered by Aerosol in a Mouse Model of Pneumonic Plague. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 3276-3284. | 1.4 | 11 |
| 253 | Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions. <i>Lancet Infectious Diseases</i> , The, 2014, 14, 498-509. | 4.6 | 745 |
| 254 | Vancomycin Exposure in Patients With Methicillin-Resistant <i>Staphylococcus aureus</i> Bloodstream Infections: How Much Is Enough?. <i>Clinical Infectious Diseases</i> , 2014, 59, 666-675. | 2.9 | 139 |
| 255 | Editorial Commentary: Are Blood Concentrations Enough for Establishing Pharmacokinetic/Pharmacodynamic Relationships?. <i>Clinical Infectious Diseases</i> , 2014, 58, 1084-1085. | 2.9 | 9 |
| 256 | <i>In Vivo</i> Activity of Cefquinome against <i>Escherichia coli</i> in the Thighs of Neutropenic Mice. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 5943-5946. | 1.4 | 19 |
| 257 | A Retrospective Review of the Clinical Experience of Linezolid with or Without Rifampicin in Prosthetic Joint Infections Treated with Debridement and Implant Retention. <i>Infectious Diseases and Therapy</i> , 2014, 3, 235-243. | 1.8 | 38 |
| 258 | Amphiphile-mediated enhanced antibiotic efficacy and development of a payload nanocarrier for effective killing of pathogenic bacteria. <i>Journal of Materials Chemistry B</i> , 2014, 2, 5818. | 2.9 | 20 |
| 259 | Optimization of physicochemical properties and safety profile of novel bacterial topoisomerase type II inhibitors (NBTIs) with activity against <i>Pseudomonas aeruginosa</i> . <i>Bioorganic and Medicinal Chemistry</i> , 2014, 22, 5392-5409. | 1.4 | 26 |
| 260 | Biocompatible Nanocarrier Fortified with a Dipyridinium-Based Amphiphile for Eradication of Biofilm. <i>ACS Applied Materials & Interfaces</i> , 2014, 6, 16384-16394. | 4.0 | 54 |
| 261 | Vancomycin pharmacokinetic models: informing the clinical management of drug-resistant bacterial infections. <i>Expert Review of Anti-Infective Therapy</i> , 2014, 12, 1371-1388. | 2.0 | 12 |
| 262 | Prolonged vs intermittent infusion of piperacillin/tazobactam in critically ill patients: A narrative and systematic review. <i>Journal of Critical Care</i> , 2014, 29, 1089-1095. | 1.0 | 28 |
| 263 | Innovative approaches to optimizing the delivery of vancomycin in individual patients. <i>Advanced Drug Delivery Reviews</i> , 2014, 77, 50-57. | 6.6 | 215 |
| 264 | Pharmacokinetics of an Extended 4-hour Infusion of Piperacillin-Tazobactam in Critically Ill Patients Undergoing Continuous Renal Replacement Therapy. <i>Pharmacotherapy</i> , 2015, 35, 600-607. | 1.2 | 18 |
| 265 | Gap Analysis of Pharmacokinetics and Pharmacodynamics in Burn Patients. <i>Journal of Burn Care and Research</i> , 2015, 36, e194-e211. | 0.2 | 24 |

| # | ARTICLE | IF | CITATIONS |
|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 266 | Cephalosporins. , 2015, , 278-292.e4. | | 18 |
| 267 | Population Pharmacokinetics and Monte Carlo Dosing Simulations of Meropenem during the Early Phase of Severe Sepsis and Septic Shock in Critically ill Patients in Intensive Care Units. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 2995-3001. | 1.4 | 66 |
| 268 | Pharmacokinetics/pharmacodynamics of a β -lactam and β -lactamase inhibitor combination: a novel approach for aztreonam/avibactam. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 2618-2626. | 1.3 | 70 |
| 269 | Antibiotic Tissue Penetration in Diabetic Foot Infections. <i>Journal of the American Podiatric Medical Association</i> , 2015, 105, 520-531. | 0.2 | 10 |
| 270 | Activity of temocillin, mecillinam, ceftazidime, and ceftazidime/avibactam against carbapenem-non-susceptible Enterobacteriaceae without carbapenemase production. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2015, 34, 2429-2437. | 1.3 | 13 |
| 271 | Thrice-weekly temocillin administered after each dialysis session is appropriate for the treatment of serious Gram-negative infections in haemodialysis patients. <i>International Journal of Antimicrobial Agents</i> , 2015, 46, 660-665. | 1.1 | 5 |
| 272 | Linezolid plasma and intrapulmonary concentrations in critically ill obese patients with ventilator-associated pneumonia: intermittent vs continuous administration. <i>Intensive Care Medicine</i> , 2015, 41, 103-110. | 3.9 | 37 |
| 273 | Concentrationâ€“response studies and modelling of the pharmacodynamics of linezolid: <i>Staphylococcus aureus</i> versus <i>Enterococcus faecium</i> . <i>International Journal of Antimicrobial Agents</i> , 2015, 45, 54-60. | 1.1 | 11 |
| 274 | How can we ensure effective antibiotic dosing in critically ill patients receiving different types of renal replacement therapy?. <i>Diagnostic Microbiology and Infectious Disease</i> , 2015, 82, 92-103. | 0.8 | 68 |
| 275 | Pharmacodynamic Evaluation of the Activities of Six Parenteral Vancomycin Products Available in the United States. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 622-632. | 1.4 | 10 |
| 276 | <i>In vitro</i> assessment of chloramphenicol and florfenicol as secondâ€“line antimicrobial agents in dogs. <i>Journal of Veterinary Pharmacology and Therapeutics</i> , 2015, 38, 443-450. | 0.6 | 12 |
| 277 | Validation of a HPLC-MS/MS assay for the determination of total and unbound concentration of temocillin in human serum. <i>Clinical Biochemistry</i> , 2015, 48, 542-545. | 0.8 | 12 |
| 278 | Pharmacokinetics of cefquinome in tilapia (<i>Oreochromis niloticus</i>) after a single intramuscular or intraperitoneal administration. <i>Journal of Veterinary Pharmacology and Therapeutics</i> , 2015, 38, 601-605. | 0.6 | 11 |
| 279 | Antimicrobial dosing in critically ill patients with sepsis-induced acute kidney injury. <i>Indian Journal of Critical Care Medicine</i> , 2015, 19, 99-108. | 0.3 | 16 |
| 280 | Pharmacokinetics of Vancomycin in Extremely Obese Patients with Suspected or Confirmed <i>Staphylococcus aureus</i> Infections. <i>Pharmacotherapy</i> , 2015, 35, 127-139. | 1.2 | 79 |
| 281 | Focus on ceftazidime-avibactam for optimizing outcomes in complicated intra-abdominal and urinary tract infections. <i>Expert Opinion on Investigational Drugs</i> , 2015, 24, 1261-1273. | 1.9 | 8 |
| 282 | Glycopeptide antibiotics: evolving resistance, pharmacology and adverse event profile. <i>Expert Review of Anti-Infective Therapy</i> , 2015, 13, 1265-1278. | 2.0 | 19 |
| 283 | Impact of the introduction of real-time therapeutic drug monitoring on empirical doses of carbapenems in critically ill burn patients. <i>Burns</i> , 2015, 41, 956-968. | 1.1 | 47 |

| # | ARTICLE | IF | CITATIONS |
|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 284 | Association between Vancomycin Day 1 Exposure Profile and Outcomes among Patients with Methicillin-Resistant Staphylococcus aureus Infective Endocarditis. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 2978-2985. | 1.4 | 68 |
| 285 | Ceftazidime-avibactam for the treatment of complicated urinary tract infections and complicated intra-abdominal infections. <i>Expert Review of Clinical Pharmacology</i> , 2015, 8, 691-707. | 1.3 | 25 |
| 286 | Response of a clinical Escherichia coli strain to repeated cefquinome exposure in a piglet tissue-cage model. <i>BMC Veterinary Research</i> , 2015, 11, 169. | 0.7 | 11 |
| 287 | Pharmacodynamic Profiling of a Siderophore-Conjugated Monocarbam in Pseudomonas aeruginosa: Assessing the Risk for Resistance and Attenuated Efficacy. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 7743-7752. | 1.4 | 64 |
| 288 | Cefazolin and linezolid penetration into sternal cancellous bone during coronary artery bypass grafting. <i>European Journal of Cardio-thoracic Surgery</i> , 2015, 48, 758-764. | 0.6 | 13 |
| 289 | A zinc complex of a neutral pyridine-based amphiphile: a highly efficient and potentially therapeutic bactericidal material. <i>Journal of Materials Chemistry B</i> , 2015, 3, 7068-7078. | 2.9 | 11 |
| 290 | Pharmacokinetics of doripenem during high volume hemodiafiltration in patients with septic shock. <i>Journal of Clinical Pharmacology</i> , 2015, 55, 438-446. | 1.0 | 6 |
| 291 | Temocillin (6 g daily) in critically ill patients: continuous infusion versus three times daily administration. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 891-898. | 1.3 | 71 |
| 292 | A retrospective analysis to estimate target trough concentration of vancomycin for febrile neutropenia in patients with hematological malignancy. <i>Clinica Chimica Acta</i> , 2015, 440, 183-187. | 0.5 | 18 |
| 293 | An Optimized Mouse Thigh Infection Model for Enterococci and Its Impact on Antimicrobial Pharmacodynamics. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 233-238. | 1.4 | 9 |
| 294 | Teicoplanin therapy for MRSA bacteraemia: a retrospective study emphasizing the importance of maintenance dosing in improving clinical outcomes. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 257-263. | 1.3 | 26 |
| 295 | Multilayered Controlled Released Topical Patch Containing Tetracycline for Wound Dressing. <i>Journal of in Silico & in Vitro Pharmacology</i> , 2016, 02, . | 0.2 | 12 |
| 296 | Pharmacokinetic/pharmacodynamic analysis of teicoplanin in patients with MRSA infections. <i>Clinical Pharmacology: Advances and Applications</i> , 2016, 8, 15. | 0.8 | 24 |
| 297 | Association between the AUC ₀₋₂₄ /MIC Ratio of Vancomycin and Its Clinical Effectiveness: A Systematic Review and Meta-Analysis. <i>PLoS ONE</i> , 2016, 11, e0146224. | 1.1 | 92 |
| 298 | Renal Function Descriptors in Neonates: Which Creatinine-Based Formula Best Describes Vancomycin Clearance?. <i>Journal of Clinical Pharmacology</i> , 2016, 56, 528-540. | 1.0 | 8 |
| 299 | Serum Î²-lactam concentrations in critically ill patients with cirrhosis: a matched case-control study. <i>Liver International</i> , 2016, 36, 1002-1010. | 1.9 | 12 |
| 300 | Pharmacodynamic Considerations in Critically Ill Patients. <i>Methods in Pharmacology and Toxicology</i> , 2016, , 537-560. | 0.1 | 1 |
| 301 | Therapeutic drug monitoring of anti-infective agents in critically ill patients. <i>Expert Review of Clinical Pharmacology</i> , 2016, 9, 961-979. | 1.3 | 98 |

| # | ARTICLE | IF | CITATIONS |
|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 302 | Preparing and administering injectable antibiotics: How to avoid playing God. <i>MÃ©decine Et Maladies Infectieuses</i> , 2016, 46, 242-268. | 5.1 | 35 |
| 303 | ExÃ© vivo pharmacokinetic/pharmacodynamic relationship of valnemulin against <i>Clostridium perfringens</i> in plasma, the small intestinal and caecal contents of rabbits. <i>Anaerobe</i> , 2016, 39, 150-157. | 1.0 | 10 |
| 305 | Vancomycin Pharmacodynamics: Optimal vs. Controversial. <i>Methods in Pharmacology and Toxicology</i> , 2016, , 261-284. | 0.1 | 0 |
| 306 | A Population and Developmental Pharmacokinetic Analysis To Evaluate and Optimize Cefotaxime Dosing Regimen in Neonates and Young Infants. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 6626-6634. | 1.4 | 26 |
| 307 | Comparative pharmacodynamics of four different carbapenems in combination with polymyxin B against carbapenem-resistant <i>Acinetobacter baumannii</i> . <i>International Journal of Antimicrobial Agents</i> , 2016, 48, 719-724. | 1.1 | 14 |
| 308 | Methodologies for Protein Binding Determination in Anti-infective Agents. <i>Methods in Pharmacology and Toxicology</i> , 2016, , 109-125. | 0.1 | 0 |
| 309 | Population pharmacokinetics of meropenem during continuous infusion in surgical ICU patients. <i>Journal of Clinical Pharmacology</i> , 2016, 56, 307-315. | 1.0 | 35 |
| 310 | Pharmacometric Approaches to Personalize Use of Primarily Renally Eliminated Antibiotics in Preterm and Term Neonates. <i>Journal of Clinical Pharmacology</i> , 2016, 56, 909-935. | 1.0 | 61 |
| 311 | Antibiotic Dosing During Continuous Renal Replacement Therapy (CRRT). , 2016, , 1-33. | | 0 |
| 312 | Pharmacokinetic and Pharmacodynamic Principles of Anti-infective Dosing. <i>Clinical Therapeutics</i> , 2016, 38, 1930-1947. | 1.1 | 112 |
| 313 | Flucloxacillin does not achieve therapeutic cerebrospinal fluid levels against methicillin-sensitive <i>Staphylococcus aureus</i> in adults: A case report and review of the literature. <i>International Journal of Antimicrobial Agents</i> , 2016, 47, 229-231. | 1.1 | 7 |
| 314 | Towards Rational Dosing Algorithms for Vancomycin in Neonates and Infants Based on Population Pharmacokinetic Modeling. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 1013-1021. | 1.4 | 53 |
| 315 | Pharmacodynamics of Ceftolozane plus Tazobactam Studied in an <i>In Vitro</i> Pharmacokinetic Model of Infection. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 515-521. | 1.4 | 18 |
| 316 | Pharmacodynamics of Ceftazidime and Avibactam in Neutropenic Mice with Thigh or Lung Infection. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 368-375. | 1.4 | 87 |
| 317 | Optimizing the Clinical Use of Vancomycin. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 2601-2609. | 1.4 | 182 |
| 318 | Population pharmacokinetics of linezolid in critically ill patients on renal replacement therapy: comparison of equal doses in continuous venovenous haemofiltration and continuous venovenous haemodiafiltration. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 464-470. | 1.3 | 36 |
| 319 | Is prolonged infusion of piperacillin/tazobactam and meropenem in critically ill patients associated with improved pharmacokinetic/pharmacodynamic and patient outcomes? An observation from the Defining Antibiotic Levels in Intensive care unit patients (DALI) cohort. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 196-207. | 1.3 | 129 |
| 320 | Population pharmacokinetics of teicoplanin and attainment of pharmacokinetic/pharmacodynamic targets in adult patients with hematological malignancy. <i>Clinical Microbiology and Infection</i> , 2017, 23, 674.e7-674.e13. | 2.8 | 29 |

| # | ARTICLE | IF | CITATIONS |
|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 322 | Comparative Pharmacodynamics of Telavancin and Vancomycin in the Neutropenic Murine Thigh and Lung Infection Models against <i>Staphylococcus aureus</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, . | 1.4 | 22 |
| 323 | Optimal teicoplanin dosage regimens for methicillin-resistant <i>Staphylococcus aureus</i> infections in endocarditis patients and renal failure patients. <i>Journal of Chemotherapy</i> , 2017, 29, 358-364. | 0.7 | 3 |
| 324 | Optimizing β -lactams treatment in critically-ill patients using pharmacokinetics/pharmacodynamics targets: are first conventional doses effective?. <i>Expert Review of Anti-Infective Therapy</i> , 2017, 15, 677-688. | 2.0 | 77 |
| 325 | Variability in Trough Total and Unbound Teicoplanin Concentrations and Achievement of Therapeutic Drug Monitoring Targets in Adult Patients with Hematological Malignancy. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, . | 1.4 | 21 |
| 326 | Delayed Second Dose Antibiotics for Patients Admitted From the Emergency Department With Sepsis. <i>Critical Care Medicine</i> , 2017, 45, 956-965. | 0.4 | 41 |
| 327 | Conventional Versus Prolonged Infusion of Meropenem in Neonates With Gram-negative Late-onset Sepsis. <i>Pediatric Infectious Disease Journal</i> , 2017, 36, 358-363. | 1.1 | 52 |
| 328 | Impact of β -lactam antibiotic therapeutic drug monitoring on dose adjustments in critically ill patients undergoing continuous renal replacement therapy. <i>International Journal of Antimicrobial Agents</i> , 2017, 49, 589-594. | 1.1 | 52 |
| 329 | Pharmacokinetic and pharmacodynamic characterization of ceftiofur crystalline free acid following subcutaneous administration in domestic goats. <i>Journal of Veterinary Pharmacology and Therapeutics</i> , 2017, 40, 429-438. | 0.6 | 9 |
| 330 | Vancomycin therapy in secondary care; investigating factors that impact therapeutic target attainment. <i>Journal of Infection</i> , 2017, 74, 320-324. | 1.7 | 1 |
| 331 | Ceftaroline efficacy against high-MIC clinical <i>Staphylococcus aureus</i> isolates in an in vitro hollow-fibre infection model. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 2796-2803. | 1.3 | 18 |
| 332 | Population pharmacokinetics of teicoplanin administered by subcutaneous or intravenous route and simulation of optimal loading dose regimen. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 2804-2812. | 1.3 | 30 |
| 333 | Pharmacodynamics of Cefepime Combined with Tazobactam against Clinically Relevant Enterobacteriaceae in a Neutropenic Mouse Thigh Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, . | 1.4 | 12 |
| 334 | Ex Vivo Model to Decipher the Impact of Extracorporeal Membrane Oxygenation on Beta-lactam Degradation Kinetics. <i>Therapeutic Drug Monitoring</i> , 2017, 39, 180-184. | 1.0 | 28 |
| 335 | Mechanisms of Action. , 2017, , 1162-1180.e1. | | 30 |
| 337 | Activity of cefquinome against extended-spectrum β -lactamase-producing <i>Klebsiella pneumoniae</i> in neutropenic mouse thigh model. <i>Journal of Veterinary Pharmacology and Therapeutics</i> , 2017, 40, 392-397. | 0.6 | 4 |
| 338 | Determining optimal dosing regimen of oral administration of dicloxacillin using Monte Carlo simulation. <i>Drug Design, Development and Therapy</i> , 2017, Volume 11, 1951-1956. | 2.0 | 4 |
| 339 | Optimizing Single-Drug Antibacterial and Antifungal Therapy. , 2017, , 157-179. | | 1 |
| 340 | Relationship between day 1 and day 2 Vancomycin area under the curve values and emergence of heterogeneous Vancomycin-intermediate <i>Staphylococcus aureus</i> (hVISA) by Etest [®] macromethod among patients with MRSA bloodstream infections: a pilot study. <i>BMC Infectious Diseases</i> , 2017, 17, 534. | 1.3 | 7 |

| # | ARTICLE | IF | CITATIONS |
|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 341 | Dosing of Ertapenem in an Extreme Obesity: A Case Report of 250â€™%kg Patient. <i>Case Reports in Critical Care</i> , 2017, 2017, 1-3. | 0.2 | 0 |
| 342 | Avibactam Pharmacokinetic/Pharmacodynamic Targets. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, . | 1.4 | 62 |
| 344 | Vancomycin Dosing and Monitoring: Critical Evaluation of the Current Practice. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2018, 43, 259-268. | 0.6 | 33 |
| 345 | Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae â€™“ Identification of LYS228. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2018, 28, 748-755. | 1.0 | 48 |
| 346 | Efficacy of Reduced Dosage of Amoxicillin in an Eradication Therapy for Helicobacter pylori Infection in Patients on Hemodialysis: A Randomized Controlled Trial. <i>Digestion</i> , 2018, 97, 163-169. | 1.2 | 4 |
| 347 | Population pharmacokinetics of total and unbound teicoplanin concentrations and dosing simulations in patients with haematological malignancy. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 995-1003. | 1.3 | 34 |
| 348 | Therapeutic Drug Monitoring of Teicoplanin in Haematological Malignancy Patients with Febrile Neutropenia and Optimizing Dosage Regimens. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2018, 123, 594-601. | 1.2 | 7 |
| 349 | Temocillin dosing in haemodialysis patients based on population pharmacokinetics of total and unbound concentrations and Monte Carlo simulations. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 1630-1638. | 1.3 | 4 |
| 350 | Population pharmacokinetics of vancomycin and AUC-guided dosing in Chinese neonates and young infants. <i>European Journal of Clinical Pharmacology</i> , 2018, 74, 921-930. | 0.8 | 41 |
| 351 | Individualising Therapy to Minimize Bacterial Multidrug Resistance. <i>Drugs</i> , 2018, 78, 621-641. | 4.9 | 48 |
| 352 | Pharmacokinetic/pharmacodynamic parameters for treatment optimization of infection due to antibiotic resistant bacteria: a summary for practical purposes in children and adults. <i>Journal of Chemotherapy</i> , 2018, 30, 65-81. | 0.7 | 18 |
| 353 | Pharmacokinetics and Pharmacodynamics of Temocillin. <i>Clinical Pharmacokinetics</i> , 2018, 57, 287-296. | 1.6 | 42 |
| 354 | Basic Pharmacokinetic Principles. , 2018, , 1-16. | | 1 |
| 355 | Antibiotic Distribution into Cerebrospinal Fluid: Can Dosing Safely Account for Drug and Disease Factors in the Treatment of Ventriculostomy-Associated Infections?. <i>Clinical Pharmacokinetics</i> , 2018, 57, 439-454. | 1.6 | 22 |
| 356 | Physical and chemical stability of ceftaroline in an elastomeric infusion device. <i>European Journal of Hospital Pharmacy</i> , 2018, 25, e115-e119. | 0.5 | 13 |
| 357 | Ventriculoperitoneal shunt infection in Haji Adam Malik Hospital, Medan. <i>IOP Conference Series: Earth and Environmental Science</i> , 2018, 125, 012092. | 0.2 | 0 |
| 358 | Optimising drug dosing in patients receiving extracorporeal membrane oxygenation. <i>Journal of Thoracic Disease</i> , 2018, 10, S629-S641. | 0.6 | 110 |
| 360 | Ceftriaxone Absorption Enhancement for Noninvasive Administration as an Alternative to Injectable Solutions. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, . | 1.4 | 5 |

| # | ARTICLE | IF | CITATIONS |
|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 361 | Pharmacokinetics and pharmacodynamics of the novel monobactam LYS228 in a neutropenic murine thigh model of infection. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 108-116. | 1.3 | 6 |
| 362 | β ² -Lactam Dosage Regimens in Septic Patients with Augmented Renal Clearance. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, . | 1.4 | 49 |
| 363 | Population pharmacokinetics and dosing optimization of cefthiamidine in children with hematologic infection. <i>Drug Design, Development and Therapy</i> , 2018, Volume 12, 855-862. | 2.0 | 4 |
| 364 | Population pharmacokinetic analysis of linezolid in patients with different types of shock: Effect of platelet count. <i>Experimental and Therapeutic Medicine</i> , 2019, 18, 1786-1792. | 0.8 | 3 |
| 365 | Optimized meropenem dosage regimens using a pharmacokinetic/pharmacodynamic population approach in patients undergoing continuous venovenous haemodiafiltration with high-adsorbent membrane. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 2979-2983. | 1.3 | 5 |
| 366 | Determining therapeutic trough ranges for linezolid. <i>Saudi Pharmaceutical Journal</i> , 2019, 27, 1061-1063. | 1.2 | 8 |
| 367 | Antibiotic resistance genes identified in wastewater treatment plant systems – A review. <i>Science of the Total Environment</i> , 2019, 697, 134023. | 3.9 | 396 |
| 368 | The importance of dosing interval in limiting vancomycin AUC with trough monitoring. <i>American Journal of Health-System Pharmacy</i> , 2020, 77, 487-492. | 0.5 | 5 |
| 369 | Simultaneous Quantification of Nine Antimicrobials by LC-MS/MS for Therapeutic Drug Monitoring in Critically Ill Patients. <i>Therapeutic Drug Monitoring</i> , 2019, 41, 29-37. | 1.0 | 25 |
| 370 | Continuous infusion of ceftolozane/tazobactam is associated with a higher probability of target attainment in patients infected with <i>Pseudomonas aeruginosa</i> . <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2019, 38, 1457-1461. | 1.3 | 33 |
| 371 | Population Pharmacokinetic Modeling and Probability of Target Attainment Analyses in Asian Patients With Community-Acquired Pneumonia Treated With Ceftaroline Fosamil. <i>Clinical Pharmacology in Drug Development</i> , 2019, 8, 682-694. | 0.8 | 6 |
| 372 | Pharmacokinetic-Pharmacodynamic Evaluation of Ertapenem for Patients with Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, . | 1.4 | 8 |
| 373 | Meropenem-Tobramycin Combination Regimens Combat Carbapenem-Resistant <i>Pseudomonas aeruginosa</i> in the Hollow-Fiber Infection Model Simulating Augmented Renal Clearance in Critically Ill Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 64, . | 1.4 | 21 |
| 375 | WCK 5222 (Cefepime-Zidebactam) Pharmacodynamic Target Analysis against Metallo-β ² -Lactamase-Producing Enterobacteriaceae in the Neutropenic Mouse Pneumonia Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, . | 1.4 | 17 |
| 376 | Optimizing the management of <i>Pseudomonas aeruginosa</i> infections with tools for the detection of resistance mechanisms and pharmacokinetic/pharmacodynamic (PK/PD) analysis. <i>Enfermedades Infecciosas Y Microbiologia Clinica (English Ed)</i> , 2019, 37, 623-625. | 0.2 | 0 |
| 377 | Antibiotics in Emergency General Surgery. , 2019, , 41-56. | | 0 |
| 378 | Ceftaroline fosamil doses and breakpoints for <i>Staphylococcus aureus</i> in complicated skin and soft tissue infections. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 425-431. | 1.3 | 31 |
| 379 | Pharmacokinetics of linezolid in critically ill patients on continuous renal replacement therapy: Influence of residual renal function on PK/PD target attainment. <i>Journal of Critical Care</i> , 2019, 50, 69-76. | 1.0 | 27 |

| # | ARTICLE | IF | CITATIONS |
|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 380 | Outpatient parenteral antimicrobial therapy and antibiotic stewardship: opponents or teammates?. <i>Infection</i> , 2019, 47, 169-181. | 2.3 | 24 |
| 381 | Evaluation of Carbapenems for Treatment of Multi- and Extensively Drug-Resistant <i>Mycobacterium tuberculosis</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, . | 1.4 | 26 |
| 382 | Population Pharmacokinetics and Dosing Optimization of Amoxicillin in Neonates and Young Infants. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, . | 1.4 | 29 |
| 383 | Augmented renal clearance in pediatric intensive care: are we undertreating our sickest patients?. <i>Pediatric Nephrology</i> , 2020, 35, 25-39. | 0.9 | 53 |
| 384 | Dual Therapy with Vonoprazan and Amoxicillin Is as Effective as Triple Therapy with Vonoprazan, Amoxicillin and Clarithromycin for Eradication of <i>Helicobacter pylori</i> . <i>Digestion</i> , 2020, 101, 743-751. | 1.2 | 87 |
| 385 | Therapeutic drug monitoring of antibiotics in critically ill patients. <i>Handbook of Analytical Separations</i> , 2020, 7, 169-183. | 0.8 | 4 |
| 386 | Dosage Regimens for Meropenem in Children with <i>Pseudomonas</i> Infections Do Not Meet Serum Concentration Targets. <i>Clinical and Translational Science</i> , 2020, 13, 301-308. | 1.5 | 9 |
| 387 | Selecting the dosage of ceftazidime-avibactam in the perfect storm of nosocomial pneumonia. <i>European Journal of Clinical Pharmacology</i> , 2020, 76, 349-361. | 0.8 | 9 |
| 388 | Pharmacokinetic variability of beta-lactams in critically ill patients: A narrative review. <i>Anaesthesia, Critical Care & Pain Medicine</i> , 2020, 39, 87-109. | 0.6 | 18 |
| 389 | Preoperative Vancomycin Administration for Surgical Site Prophylaxis. <i>Anesthesia and Analgesia</i> , 2020, 130, 1435-1444. | 1.1 | 0 |
| 390 | Comparison of extended versus intermittent infusion of antipseudomonal beta-lactams for the treatment of critically ill patients with respiratory infections: A systematic review and meta-analysis. <i>International Journal of Infectious Diseases</i> , 2020, 98, 41-50. | 1.5 | 8 |
| 391 | What is the optimal loading dose of broad-spectrum β -lactam antibiotics in septic patients? Results from pharmacokinetic simulation modelling. <i>International Journal of Antimicrobial Agents</i> , 2020, 56, 106113. | 1.1 | 17 |
| 392 | Early therapeutic monitoring of β -lactams and associated therapy outcomes in critically ill patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 3644-3651. | 1.3 | 44 |
| 393 | Population Pharmacokinetics of Teicoplanin in Preterm and Term Neonates: Is It Time for a New Dosing Regimen?. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, . | 1.4 | 8 |
| 394 | Optimizing Antibiotic Treatment Strategies for Neonates and Children: Does Implementing Extended or Prolonged Infusion Provide any Advantage?. <i>Antibiotics</i> , 2020, 9, 329. | 1.5 | 11 |
| 395 | Therapeutic monitoring of vancomycin for serious methicillin-resistant <i>Staphylococcus aureus</i> infections: A revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists. <i>American Journal of Health-System Pharmacy</i> , 2020, 77, 835-864. | 0.5 | 640 |
| 396 | Population Pharmacokinetics and Target Attainment of Cefepime in Critically Ill Patients and Guidance for Initial Dosing. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, . | 1.4 | 25 |
| 397 | Clinical efficacy and safety in patients treated with teicoplanin with a target trough concentration of 20 µg/mL using a regimen of 12 mg/kg for five doses within the initial 3 days. <i>BMC Pharmacology & Toxicology</i> , 2020, 21, 50. | 0.8 | 21 |

| # | ARTICLE | IF | CITATIONS |
|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 398 | Should Therapeutic Monitoring of Vancomycin Based on Area under the Curve Become Standard Practice for Patients with Confirmed or Suspected Methicillin-Resistant <i>Staphylococcus aureus</i> Infection?. <i>Canadian Journal of Hospital Pharmacy</i> , 2020, 73, . | 0.1 | 2 |
| 399 | Teicoplanin and therapeutic drug monitoring: An update for optimal use in different patient populations. <i>Journal of Infection and Chemotherapy</i> , 2020, 26, 900-907. | 0.8 | 19 |
| 400 | Impact of augmented renal clearance on the pharmacokinetics of linezolid: Advantages of continuous infusion from a pharmacokinetic/pharmacodynamic perspective. <i>International Journal of Infectious Diseases</i> , 2020, 93, 329-338. | 1.5 | 36 |
| 401 | Use of Monte Carlo simulation to optimize antibiotic selection for bloodstream infections caused by Enterobacteriaceae in Shandong Province, China. <i>Diagnostic Microbiology and Infectious Disease</i> , 2020, 97, 115039. | 0.8 | 1 |
| 402 | Population pharmacokinetics and dosing optimization of azlocillin in neonates with early-onset sepsis: a real-world study. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 699-709. | 1.3 | 11 |
| 403 | The Pharmacodynamic-Toxicodynamic Relationship of AUC and C_{max} in Vancomycin-Induced Kidney Injury in an Animal Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, . | 1.4 | 13 |
| 404 | Prolonged infusion of linezolid is associated with improved pharmacokinetic/pharmacodynamic (PK/PD) profiles in patients with external ventricular drains. <i>European Journal of Clinical Pharmacology</i> , 2021, 77, 79-86. | 0.8 | 5 |
| 405 | How to optimize administration of ceftoxitin for the treatment of extended spectrum producing Enterobacteriaceae-related infection?. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2021, 40, 1393-1397. | 1.3 | 3 |
| 406 | Wastewater Treatment Plants as emerging source of antibiotic resistance. , 2021, , 239-269. | | 4 |
| 407 | Ceftazidime-Avibactam Use for <i>Klebsiella pneumoniae</i> Carbapenemase-Producing <i>K. pneumoniae</i> Infections: A Retrospective Observational Multicenter Study. <i>Clinical Infectious Diseases</i> , 2021, 73, 1664-1676. | 2.9 | 130 |
| 408 | Optimal trough concentration of teicoplanin for the treatment of methicillin-resistant <i>Staphylococcus aureus</i> infection: A systematic review and meta-analysis. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2021, 46, 622-632. | 0.7 | 13 |
| 409 | Population Pharmacokinetics of Piperacillin in Non-Critically Ill Patients with Bacteremia Caused by Enterobacteriaceae. <i>Antibiotics</i> , 2021, 10, 348. | 1.5 | 3 |
| 410 | AUCs and 123s: a critical appraisal of vancomycin therapeutic drug monitoring in paediatrics. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 2237-2251. | 1.3 | 15 |
| 411 | Pharmacokinetic/Pharmacodynamic Dosage Individualization of Suppressive Beta-Lactam Therapy Administered by Subcutaneous Route in Patients With Prosthetic Joint Infection. <i>Frontiers in Medicine</i> , 2021, 8, 583086. | 1.2 | 7 |
| 412 | Should Therapeutic Drug Monitoring Based on the Vancomycin Area Under the Concentration-Time Curve Be Standard for Serious Methicillin-Resistant <i>Staphylococcus aureus</i> Infections? No. <i>Clinical Infectious Diseases</i> , 2021, 72, 1502-1506. | 2.9 | 14 |
| 413 | Individualized Vancomycin Dosing with Therapeutic Drug Monitoring and Pharmacokinetic Consultation Service: A Large-Scale Retrospective Observational Study. <i>Drug Design, Development and Therapy</i> , 2021, Volume 15, 423-440. | 2.0 | 5 |
| 414 | Pharmacokinetic/pharmacodynamic evaluation of teicoplanin against <i>Staphylococcus aureus</i> in a murine thigh infection model. <i>Journal of Global Antimicrobial Resistance</i> , 2021, 24, 83-87. | 0.9 | 8 |
| 415 | Comment on: The case for conservative pharmacotherapy. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 1951-1952. | 1.3 | 1 |

| # | ARTICLE | IF | CITATIONS |
|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|-----------|
| 416 | Pharmacological and clinical profile of cefiderocol, a siderophore cephalosporin against gram-negative pathogens. <i>Expert Review of Clinical Pharmacology</i> , 2021, 14, 777-791. | 1.3 | 4 |
| 417 | The case for “conservative pharmacotherapy” authors’ response. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 1952-1953. | 1.3 | 0 |
| 418 | Cefepime Population Pharmacokinetics and Target Attainment in Critically Ill Patients on Continuous Renal Replacement Therapy. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, . | 1.4 | 7 |
| 419 | Quantification of persister formation of <i>Escherichia coli</i> leveraging electronic cell counting and semi-mechanistic pharmacokinetic/pharmacodynamic modelling. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 2088-2096. | 1.3 | 6 |
| 420 | Novel Pharmacokinetic/Pharmacodynamic Parameters Quantify the Exposure-Effect Relationship of Levofloxacin against Fluoroquinolone-Resistant <i>Escherichia coli</i> . <i>Antibiotics</i> , 2021, 10, 615. | 1.5 | 4 |
| 421 | Prevalence of Antibiotic Resistance Genes in Pharmaceutical Wastewaters. <i>Water (Switzerland)</i> , 2021, 13, 1731. | 1.2 | 3 |
| 422 | Optimizing Antimicrobial Drug Dosing in Critically Ill Patients. <i>Microorganisms</i> , 2021, 9, 1401. | 1.6 | 27 |
| 423 | Optimizing antimicrobial use: challenges, advances and opportunities. <i>Nature Reviews Microbiology</i> , 2021, 19, 747-758. | 13.6 | 51 |
| 424 | Optimal Sampling Strategy and Threshold of Serum Vancomycin Concentration in Elderly Japanese Patients undergoing High-flux Hemodialysis. <i>Therapeutic Drug Monitoring</i> , 2021, Publish Ahead of Print, . | 1.0 | 0 |
| 425 | Individualized precision dosing approaches to optimize antimicrobial therapy in pediatric populations. <i>Expert Review of Clinical Pharmacology</i> , 2021, 14, 1383-1399. | 1.3 | 8 |
| 426 | Treatment of Native Valve Endocarditis: General Principles and Therapy for Specific Organisms. , 2006, , 121-183. | | 2 |
| 427 | Treatment of Endocarditis. , 2016, , 181-280. | | 1 |
| 428 | Mechanisms of Resistance in <i>Haemophilus influenzae</i> and <i>Moraxella catarrhalis</i> . , 2017, , 867-888. | | 3 |
| 429 | Third World Diseases. <i>Topics in Medicinal Chemistry</i> , 2011, , . | 0.4 | 2 |
| 430 | Cephalosporins. , 2010, , 323-339. | | 3 |
| 433 | Clinical Validation of Therapeutic Drug Monitoring of Imipenem in Spent Effluent in Critically Ill Patients Receiving Continuous Renal Replacement Therapy: A Pilot Study. <i>PLoS ONE</i> , 2016, 11, e0153927. | 1.1 | 10 |
| 434 | Infection-stage adjusted dose of beta-lactams for parsimonious and efficient antibiotic treatments: A <i>Pasteurella multocida</i> experimental pneumonia in mice. <i>PLoS ONE</i> , 2017, 12, e0182863. | 1.1 | 13 |
| 435 | Pharmacodynamics of Antimicrobials: General Concepts and Applications. <i>Infectious Disease and Therapy</i> , 2007, , 1-20. | 0.0 | 42 |

| # | ARTICLE | IF | CITATIONS |
|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 436 | A Pharmacokinetic and Pharmacodynamic Study on Intravenous Cefazedone Sodium in Patients with Community-acquired Pneumonia. Chinese Medical Journal, 2015, 128, 1160-1164. | 0.9 | 1 |
| 437 | Assessment of Susceptibility, Pharmacodynamics, and Therapeutic Response for Interpretation of Piperacillin-Tazobactam <i>in Vitro</i> Activity in the Treatment of <i>Pseudomonas aeruginosa</i>; Infection. Open Journal of Medical Microbiology, 2012, 02, 101-109. | 0.1 | 2 |
| 438 | Vancomycin. Journal of the American Academy of Orthopaedic Surgeons, The, 2005, 13, 89-92. | 1.1 | 14 |
| 439 | Performance of Various Pharmacokinetic Parameters in Predicting Vancomycin Serum Concentrations. Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences), 2008, 34, 1-12. | 0.0 | 5 |
| 440 | Applying Cefepime Population Pharmacokinetics to Critically Ill Patients Receiving Continuous Renal Replacement Therapy. Antimicrobial Agents and Chemotherapy, 2022, 66, AAC0161121. | 1.4 | 4 |
| 441 | Population pharmacokinetics of cefepime in critically ill patients receiving extracorporeal membrane oxygenation (an ASAP ECMO study). International Journal of Antimicrobial Agents, 2021, 58, 106466. | 1.1 | 12 |
| 442 | ¿En qué ayuda el antibiograma al médico clínico en la atención de sus pacientes?. Revista Chilena De Infectología, 0, 21, . | 0.0 | 0 |
| 443 | Clinical Pharmacology of Antimicrobial Agents: 2.PK/PD in Experimental Models. Japanese Journal of Clinical Pharmacology and Therapeutics, 2005, 36, 173-176. | 0.1 | 0 |
| 444 | Evaluation of TDM System for Setting of Initial Anti-MRSA Drug Dosages by Pharmacists at Two Hospitals. Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences), 2006, 32, 985-996. | 0.0 | 5 |
| 445 | Dose Adjustment and Pharmacokinetics of Antibiotics in Severe Sepsis and Septic Shock. , 2007, , 122-146. | | 1 |
| 446 | é†äæ²»ç™,é~äÿä«ãšãã,ãf†ã,ããf—ãf©ãfãf³ã©ç”æ³•ç”é†ãæèèŽ. Journal of the Japanese Society of Intensive Care Medicine, 2008, , 97-136. | | 2 |
| 447 | Dose Adjustment and Pharmacodynamic Considerations for Antibiotics in Severe Sepsis and Septic Shock. , 2008, , 97-136. | | 2 |
| 448 | ANTIBACTERIAL THERAPEUTIC AGENTS. , 2009, , 3178-3227. | | 5 |
| 449 | Mechanisms of Resistance in Haemophilus influenzae and Moraxella catarrhalis. , 2009, , 783-801. | | 0 |
| 451 | Mechanisms of action. , 2010, , 1288-1307. | | 0 |
| 453 | Fluctuation in PK/PD Parameters and Adverse Reactions of Vancomycin. Iryo Yakugaku (Japanese) Tj ETQq1 1 0.784314 rgBT /Overlock 10 T | 0.0 | 0 |
| 454 | Evaluation of Japanese GFR Estimation Equation for Setting Initial Dose of Vancomycin-Comparison with Cockcroft & Gault equation-. Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and) Tj ETQq0 0 0rgBT /Overlock 10 T | | 0 |
| 456 | Antimicrobial Pharmacokinetics and Pharmacodynamics in the Treatment of Nosocomial Gram-negative Infections. Advances in Pharmacoepidemiology & Drug Safety, 2013, 01, . | 0.1 | 1 |

| # | ARTICLE | IF | CITATIONS |
|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 457 | Antibiotics in Treatment of Periprosthetic Joint Infections. , 2014, , 107-123. | | 0 |
| 458 | Study of VCM 2 1/4g/m<i>l</i> of <i>S. aureus</i> in the Micro Scan Walk Away POS series panel. Japanese Journal of Medical Technology, 2014, 63, 90-93. | 0.0 | 0 |
| 459 | Clinical Testing of a New Drug. Springer Series in Pharmaceutical Statistics, 2017, , 1-18. | 0.0 | 0 |
| 460 | Antibiotic Pharmacodynamics. , 2018, , 17-29. | | 2 |
| 461 | Antibiotic and Antifungal Therapy in the ICU. , 2018, , 373-389. | | 1 |
| 462 | Optimizing the management of Pseudomonas aeruginosa infections with tools for the detection of resistance mechanisms and pharmacokinetic/pharmacodynamic (PK/PD) analysis. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2019, 37, 623-625. | 0.3 | 1 |
| 463 | Challenges of Vancomycin Dosing and Therapeutic Monitoring in Neonates. Journal of Pediatric Pharmacology and Therapeutics, 2020, 25, 476-484. | 0.3 | 10 |
| 464 | Therapeutic Drug Monitoring of Antibiotics: Defining the Therapeutic Range. Therapeutic Drug Monitoring, 2022, 44, 19-31. | 1.0 | 31 |
| 465 | Should Therapeutic Monitoring of Vancomycin Based on Area under the Curve Become Standard Practice for Patients with Confirmed or Suspected Methicillin-Resistant Infection?. Canadian Journal of Hospital Pharmacy, 2020, 73, 232-237. | 0.1 | 3 |
| 466 | Clinical Testing of a New Drug. Springer Series in Pharmaceutical Statistics, 2021, , 1-21. | 0.0 | 0 |
| 467 | Enhanced loading dose of teicoplanin for three days is required to achieve a target trough concentration of 20 1/4g/mL in patients receiving continuous venovenous haemodiafiltration with a low flow rate. Journal of Infection and Chemotherapy, 2022, 28, 232-237. | 0.8 | 4 |
| 468 | Appropriate Use of Glycopeptide Antibiotics and Therapeutic Drug Monitoring for Invasive Infections. Korean Journal of Medicine, 2021, 96, 463-477. | 0.1 | 0 |
| 469 | Clinical practice guidelines for therapeutic drug monitoring of teicoplanin: a consensus review by the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring. Journal of Antimicrobial Chemotherapy, 2022, 77, 869-879. | 1.3 | 23 |
| 470 | Modelled Target Attainment after Temocillin Treatment in Severe Pneumonia: Systemic and Epithelial Lining Fluid Pharmacokinetics of Continuous versus Intermittent Infusions. Antimicrobial Agents and Chemotherapy, 2022, 66, AAC0205221. | 1.4 | 13 |
| 471 | Pharmacokinetics of Cefazolin in Patients With Obesity Undergoing Surgery Requiring Cardiopulmonary Bypass. Journal of Cardiothoracic and Vascular Anesthesia, 2022, 36, 2942-2947. | 0.6 | 2 |
| 472 | Validation of Vancomycin Area under the Concentrationâ€”Time Curve Estimation by the Bayesian Approach Using One-Point Samples for Predicting Clinical Outcomes in Patients with Methicillin-Resistant Staphylococcus aureus Infections. Antibiotics, 2022, 11, 96. | 1.5 | 20 |
| 473 | Concise Clinical Review of Hematologic Toxicity of Linezolid in Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis: Role of Mitochondria. Tuberculosis and Respiratory Diseases, 2022, 85, 111-121. | 0.7 | 8 |
| 476 | Pharmacokinetics and pharmacokinetic/pharmacodynamic-based dosing regimens of long-acting oxytetracycline in Nile tilapia (Oreochromis niloticus) broodstock to minimize selection of drug resistance. Aquaculture, 2022, 557, 738302. | 1.7 | 1 |

| # | ARTICLE | IF | CITATIONS |
|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 477 | Population pharmacokinetics and dosing optimization of mezlocillin in neonates and young infants. <i>Journal of Antimicrobial Chemotherapy</i> , 0, . | 1.3 | 2 |
| 478 | The primary pharmacology of ceftazidime/avibactam: <i>in vivo</i> translational biology and pharmacokinetics/pharmacodynamics (PK/PD). <i>Journal of Antimicrobial Chemotherapy</i> , 2022, 77, 2341-2352. | 1.3 | 9 |
| 479 | Harnessing Clinical Trial and Real-World Data Towards an Understanding of Sex Effects on Drug Pharmacokinetics, Pharmacodynamics and Efficacy. <i>Frontiers in Pharmacology</i> , 0, 13, . | 1.6 | 4 |
| 480 | Optimizing Antimicrobial Therapy by Integrating Multi-Omics With Pharmacokinetic/Pharmacodynamic Models and Precision Dosing. <i>Frontiers in Pharmacology</i> , 0, 13, . | 1.6 | 2 |
| 481 | Using Machine Learning To Define the Impact of Beta-Lactam Early and Cumulative Target Attainment on Outcomes in Intensive Care Unit Patients with Hospital-Acquired and Ventilator-Associated Pneumonia. <i>Antimicrobial Agents and Chemotherapy</i> , 2022, 66, . | 1.4 | 12 |
| 482 | Population Pharmacokinetics of Temocillin Administered by Continuous Infusion in Patients with Septic Shock Associated with Intra-Abdominal Infection and Ascitic Fluid Effusion. <i>Antibiotics</i> , 2022, 11, 898. | 1.5 | 4 |
| 483 | Norvancomycin for the treatment of central nervous system MRSA infections: A randomized controlled trial. <i>European Journal of Pharmaceutical Sciences</i> , 2022, 177, 106266. | 1.9 | 2 |
| 484 | Binding of temocillin to plasma proteins <i>in vitro</i> and <i>in vivo</i> : the importance of plasma protein levels in different populations and of co-medications. <i>Journal of Antimicrobial Chemotherapy</i> , 2022, 77, 2742-2753. | 1.3 | 3 |
| 485 | Reproducible Quantification of Unbound Fractions of Four Beta-lactam Antibiotics: Ultrafiltration versus Microdialysis of Spiked Healthy Donor Plasma. <i>Therapeutic Drug Monitoring</i> , 2022, Publish Ahead of Print, . | 1.0 | 0 |
| 486 | Efficacy and safety of high-dose esomeprazole+amoxicillin dual therapy for <i>Helicobacter pylori</i> rescue treatment: a multicenter, prospective, randomized, controlled trial. <i>Chinese Medical Journal</i> , 2022, 135, 1707-1715. | 0.9 | 11 |
| 487 | Tissue Penetration of Antimicrobials in Intensive Care Unit Patients: A Systematic Review” Part I. <i>Antibiotics</i> , 2022, 11, 1164. | 1.5 | 9 |
| 488 | Tissue Penetration of Antimicrobials in Intensive Care Unit Patients: A Systematic Review” Part II. <i>Antibiotics</i> , 2022, 11, 1193. | 1.5 | 7 |
| 489 | Meropenem Population Pharmacokinetics and Dosing Regimen Optimization in Critically Ill Children Receiving Continuous Renal Replacement Therapy. <i>Clinical Pharmacokinetics</i> , 0, . | 1.6 | 0 |
| 490 | Comparison of Open-Access, Trough-Only Online Calculators Versus Trapezoidal Method for Calculation of Vancomycin Area Under the Curve (AUC). <i>Annals of Pharmacotherapy</i> , 0, , 106002802211388. | 0.9 | 2 |
| 491 | Evaluation of drug prescribing patterns and therapeutic drug monitoring practice using electronic medical records. <i>Scientific Reports</i> , 2022, 12, . | 1.6 | 0 |
| 492 | Vonoprazan and high-dose amoxicillin dual therapy for <i>Helicobacter pylori</i> first-line eradication: A single-arm, interventional study. <i>JGH Open</i> , 2023, 7, 55-60. | 0.7 | 5 |
| 493 | <sc>VANCOMycin</sc> dose adjustments comparing trough levels to the ratio of the area under de curve to the minimum inhibitory concentration method using a <sc>BAYESian</sc> approach: A feasibility study. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2022, 47, 2335-2344. | 0.7 | 2 |
| 494 | Beta-lactam target attainment and associated outcomes in patients with bloodstream infections. <i>International Journal of Antimicrobial Agents</i> , 2023, 61, 106727. | 1.1 | 14 |

| # | ARTICLE | IF | CITATIONS |
|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 495 | Evaluation of cefuroxime concentration in the intra- and extrathecal compartments of the lumbar spine – an experimental porcine study. <i>British Journal of Pharmacology</i> , 0, , . | 2.7 | 0 |
| 496 | What Is the Best Vancomycin Therapeutic Drug Monitoring Parameter to Assess Efficacy? A Critical Review of Experimental Data and Assessment of the Need for Individual Patient Minimum Inhibitory Concentration Value. <i>Microorganisms</i> , 2023, 11, 567. | 1.6 | 1 |
| 497 | Predictive Factors of Piperacillin Exposure and the Impact on Target Attainment after Continuous Infusion Administration to Critically Ill Patients. <i>Antibiotics</i> , 2023, 12, 531. | 1.5 | 0 |
| 498 | Optimizing pharmacotherapy regimens in adult patients receiving extracorporeal membrane oxygenation: A narrative review for clinical pharmacists. <i>JACCP Journal of the American College of Clinical Pharmacy</i> , 2023, 6, 621-631. | 0.5 | 1 |
| 499 | Population pharmacokinetics and dosing optimisation of imipenem in critically ill patients. <i>European Journal of Hospital Pharmacy</i> , 0, , ejhpharm-2022-003403. | 0.5 | 1 |
| 500 | A retrospective analysis to estimate trough concentrations of teicoplanin in patients with suspected or documented Gram-positive infections. <i>Brazilian Journal of Pharmaceutical Sciences</i> , 0, 59, . | 1.2 | 0 |